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My research project was focused on the study of triple negative breast cancer (TNBC), which is highly 
aggressive and unresponsive to common treatments. One of the factors responsible for the aggressive 
features of TNBC is the High mobility group (HMG) A1 protein, a master regulator of the gene 
transcription, whose high expression level has been correlated with a higher grade in breast cancer. 
To deepen the knowledge about HMGA1 in breast cancer, we sequenced the RNA collected from a 
model of TNBC, the MDA-MB-231 cell line, upon HMGA1 silencing; thanks to a bioinformatic 
analysis, we unraveled molecular partners HMGA1 could cooperate with in regulating common 
downstream gene networks in breast cancer and among them we selected Forkhead box M1 (FOXM1) 
transcription factor, chosen for its role in breast carcinogenesis. Firstly, we validated several 
HMGA1/FOXM1 targets by qRT-PCR after HMGA1 and FOXM1 silencing in TNBC cell lines. 
Moreover, the depletion of FOXM1 in TNBC cells leads to the acquisition of a more epithelial-like 
phenotype, with a disruption of the vimentin network, a typical marker of the mesenchymal 
phenotype, and the diminution of the migratory ability of TNBC cells, results similar to those we 
obtained upon HMGA1 silencing, and further accentuated by the co-silencing of the two factors. In 
addition, upon HMGA1 depletion in TNBC cell lines and HEK-293T, FOXM1 translocates from the 
nucleus to the cytoplasm, suggesting that HMGA1 could modulate FOXM1 subcellular localization 
and activity. To validate this hypothesis, we performed a luciferase reporter assay, by transfecting the 
HEK293T cells with a construct containing a portion of the promoter of a known HMGA1/FOXM1 
target, the Vascular Endothelial growth factor (VEGFA) A. By co-transfecting the two factors, we 
found that HMGA1 increases the transcriptional activity of FOXM1 on VEGFA promoter and with 
several deletion constructs we restricted the region responsible for this activity. Considering that the 
VEGFA is one of the main inducer of angiogenesis, a hallmark in breast cancer, we investigated how 
HMGA1 and FOXM1 are involved in this process. Thus, we treated the HUVEC endothelial cells 
with supernatants of MDA-MB-231 depleted of HMGA1 and/or FOXM1 and we observed that the 
proliferation, the migration, and the ability to form a vessel-like network of HUVEC cells were 
affected. We finally validated in vivo that HMGA1 and FOXM1 synergistically regulate the neo-
angiogenesis in Zebrafish larvae. Hence, we demonstrated that HMGA1 and FOXM1 are involved in 
the regulation of the same gene network in TNBC and that HMGA1 influences the FOXM1 cellular 
localization and transcriptional activity. We showed also that breast tumor cells, on the driving force 
of HMGA1 and FOXM1, modulate the angiogenic process carried out by endothelial cells, both in 
vitro and in vivo. 
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1. BREAST CANCER 
 
1.1 Mammary gland structure  
 
The breast is the female organ designated to the milk production and thus to the nourishment of new-
borns. It is an exocrine gland located in the chest wall, atop the pectoralis muscles (Fig. 1a). It is made 
up with two functional units, the alveoli and the ducts. The alveoli are then grouped in lobules and 
are the structures in which milk is synthetized. The milk is then drained into a lactiferous duct which 
carries the milk from the lobule to the nipple. Both the lobules and the ducts are composed by a bi-
layered cell structure, with an inner part of luminal epithelial cells and an outer layer of contractile 
myoepithelial cells, controlling the ejection of the milk throughout ducts (Fig. 1b). These cells are 
then surrounded by a stroma of adipocytes and fibroblasts infiltrated by blood and lymphatic vessels 
(Oakes et al., 2014).  
 
 
 
Figure 1: a) Structure of the mammary gland; b) Bilayered structure of mammary gland lobules 
 Adapted by 
http://humanbiologylab.pbworks.com/w/page/104941359/Histology%20of%20the%20Mammary%20Gland 
 
In vitro differentiation assays on primary epithelial cells proved the origin of these cells from common 
committed progenitors derived in turn from multipotent Mammary Stem cells (MaSC), present also 
in adult breast tissue as niches in mammary gland and characterized by self-renewal property (Prat 
and Perou, 2009). These cells have a key role in supporting the cellular turnover taking place during 
and after pregnancy (Macias and Hinck, 2012). Mammary gland development occurs in three 
different stages: embryonal, pubertal and reproductive. At the end of the embryonic development, a 
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rudimental ductal structure has formed; then, the gland grows allometrically, keeping up with overall 
body development, until puberty when the epithelium strongly proliferates, branching in numerous 
ducts with terminal endbuds or alveoli, filling the fat pad under the influence of the ovarian steroid 
hormone oestrogen and growth hormones (GH) (Macias and Hinck, 2012; Sternlicht, 2006). At the 
moment of pregnancy, the epithelial cells cleave and differentiate into distinct alveoli, becoming 
milk-secreting lobules during lactation. Some of these steps take place also during oestrus cycles, 
with a mild proliferation and differentiation of the mammary gland, followed by its involution. The 
hormone mainly responsible for this extensive branching and alveologenesis is progesterone, another 
steroid hormone released by the ovaries. Together with prolactin, progesterone brings to the alveoli 
differentiation. After weaning, these structures then collapse, and the mammary gland undergoes 
apoptosis, bringing to a pre-pregnancy state involution. In menopause, a complete involution takes 
place, with the fat cells replacing the mammary gland epithelial cells and the surrounding connective 
tissue (Macias and Hinck, 2012; Oakes et al., 2014).  
The deregulation of pathways controlling hormones or other factors usually involved in the normal 
development of the mammary gland could bring to an uncontrollable growth of glandular epithelial 
cells, leading in turn to the breast cancer onset. If not treated, malignant cells can invade surrounding 
or distal tissues and organs, primarily lungs, brain and bones (Minn et al., 2005; Scully et al., 2012). 
 
1.2 Breast cancer  
 
Breast cancer is the most common malignancy in women worldwide, both in less and in more 
developed countries, with nearly 1,7 million estimated cases in 2012, taking into account the 25% of 
all tumours. It is the first and the second cause of cancer related death among women in the less and 
more developed countries respectively and the fifth cause of cancer related death among all cancers 
(Torre et al., 2015). The data presented above underline how much aggressive breast cancer is and 
the urgency to keep on studying the progression of this disease. 
Breast cancer is an extremely heterogeneous disease, subdivided in several subtypes with different 
biological features and clinical outcomes, aspect that in turn deeply impinges on the choice of an 
adequate therapy (Vargo-Gogola and Rosen, 2007).        
The breast cancer patients are classified according to the 2012 Who Classification of tumours of the 
breast (International Agency for research on cancer), which stratifies them basing on the 
histopathological type, tumor grading and staging, biomarkers expression and molecular profiling 
(Gannon et al., 2013).  
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At the moment of the diagnosis, one of the first evaluation made by physicians is the examination of 
bioptics breast specimens. The histological evaluation leads to roughly divide breast cancer in 
carcinoma in situ or infiltrating carcinoma. The in situ malignancy can be further classified in ductal 
carcinoma in situ (DCIS) or lobular (LCIS), less common with respect to the ductal type. The invasive 
carcinoma encompasses a wide variety of histological subtypes, among which the infiltrating ductal 
carcinoma is the most common, accounting for 70-80% of invasive lesions (Malhotra et al., 2010). In 
addition, the aggressiveness of breast cancer is categorized by the evaluation of the grade of the 
tumour basing on the differentiating status, according to the Nottighman Histologic score. Further 
information about the size of the primary tumour (T), the status of regional axillary lymph nodes (N) 
and the presence of distant metastasis (M) at diagnosis, according to the Classification of Malignant 
Tumours (TNM), lead to the classification of breast cancer in five stages (Webber et al., 2014). The 
lower the grade and the stage values are, the less aggressive the breast cancer is.  
In order to better decide the patients who could benefit from a specific treatment, the evaluation of 
biomarkers, such as oestrogen, progesterone, epidermal growth factor receptors and Ki67 in breast 
cancers has been widely used in the past decades (Weigel and Dowsett, 2010). As highlighted before, 
the hormones oestrogen and progesterone play a crucial role in mammary gland development and 
differentiation, and their deregulation often leads to cancer development. For this reason, the 
evaluation of oestrogen and progesterone receptors (ER and PR) status is of high importance, 
considering that nearly 70% of invasive breast carcinoma express high levels of these receptors. The    
ER and PR positive breast cancers are usually treatable by hormone-interfering compounds, such as 
Tamoxifen, Fulvestrant and aromatase inhibitors (Gu et al., 2016; Moran, 2015). The amplification 
and the overexpression of the Epidermal growth factor receptor 2 (HER2) characterize approximately 
15% of all primary tumours and was firstly identified as an indicator of prognosis. Indeed, patients 
with high levels of HER2 tend to relapse and have a shorter overall survival. Nevertheless, these 
patients can benefit from the use of anti-HER2 targeted therapies, such as Trastuzumab and Lapatinib 
(Weigel and Dowsett, 2010). Finally, Ki67 nuclear protein is used as a biomarker, being present in 
the active phases of the cell cycle thus indicating the proliferating cells (Scholzen and Gerdes, 2000). 
Ki67 evaluation is less adopted compared to the above-mentioned receptors status, due to the lack of 
a generally accepted system. The advent of high-throughput techniques, with microarray-based gene 
expression profiles, gave the physicians a further opportunity to more accurately stratify breast cancer 
patients in specific molecular subtypes with different overall survival rate, clinical outcome and 
ultimately treatment responses (Sørlie et al., 2001; Van ’t Veer et al., 2002), as represented in figure 
2 in which 115 breast tumours are clustered in a dendrograms showing the different subtypes of breast 
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cancer, each of them with a different outcome (Vargo-Gogola and Rosen, 2007) . Indeed, breast 
cancer can be clustered in five molecular subtypes: 
a. Luminal A characterized by the positivity to ER and PR presence and negative for HER2. They 
are low-grade and tend to have a good prognosis. 
b. Luminal B characterized, as Luminal A, by the positivity to ER and PR presence, but it shows a 
more aggressive phenotype and a worse prognosis compared to the A, as it expresses high level of 
HER2. 
c. HER2-like with an amplification and/or overexpression of epidermal growth factor receptor 2, 
with an unfavourable prognosis but the possibility to adopt targeted treatment 
d. Normal-like genetically recalling a normal breast epithelium. There are few studies on this subtype 
and their clinical significance remains undetermined. Some researchers consider them technical 
artefacts from high contamination with normal tissue during microarrays (Weigelt et al., 2010).  
e. Basal-like breast cancer which is the most aggressive subtype with a high histological grade and 
the worst overall survival outcome.  
 
 
 
Figure 2: a) molecular classification of breast cancer subtypes basing on gene expression profile; b) prognostic outcome 
of different molecular subtypes of breast cancer. Adapted by Vargo-Gogola and Rosen, 2007 
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1.2.1 Basal-like breast cancer subtype 
 
Basal-like breast cancer accounts for 15% of all breast cancers and encompasses a highly 
heterogeneous group of diseases. This molecular subtype is characterized by a gene expression profile 
similar to that of the basal-myoepithelial layer of the normal breast (Foulkes et al., 2010). Indeed, the 
basal-like breast cancer cells express high level of Cytokeratins 5/6, -14 and -17 and laminin. Basal-
like breast cancer frequently shows mutations in tumor protein 53 (TP 53) gene and inactivation of 
the retinoblastoma (Rb) pathway (Heitz et al., 2009). The origin of basal-like breast cancer cells are 
still debated: indeed, it is still controversial whether basal-like breast cancer cells originate from 
mammary stem cells or are a product of an EMT event involving the luminal cells which lose their 
apicobasal polarity, acquire the ability to migrate and express basal/mesenchymal markers (Foulkes 
et al., 2009; Skibinski and Kuperwasser, 2015). Basal-like cancers are associated with high 
histological and nuclear grade and most of them are infiltrating ductal tumors with solid growth 
pattern, aggressive clinical behaviour, with a weak correlation between the size of primary tumour 
and the probability of survival, and a high rate of metastasis to the brain or lung (Heitz et al., 2009). 
The basal-like breast tumours lacking protein expression of oestrogen, progesterone and epidermal 
growth factor receptors are defined as triple negative breast cancer (TNBC). Basal-like breast cancer 
and TNBC are not completely synonymous, even though the majority of triple negative breast cancers 
are also basal-like. Indeed, TNBC comprises other subtypes of breast cancers such as the claudin-low 
tumours, composed by cells with stem cell-like properties (Foulkes et al., 2010). Patients affected by 
TNBC do not benefit from specific treatments, such as endocrine therapy or trastuzumab. Indeed, 
chemotherapy is the only mainstay of systemic treatment.  
 
1.3 Cancer Hallmarks 
 
Cancer is a heterogeneous disease that develops through the accumulation of mutations and genetic 
changes in normal cells. In a multistep process, neoplastic cells acquire a succession of hallmark 
capabilities. In 2000, Hanahan and Weinberg classified these tumour features in six hallmarks, 
simplifying the biology of cancer, and subsequently, in 2011, they modified their original formulation 
adding four new emerging hallmarks (Hanahan and Weinberg, 2000, 2011). These include: (i) 
unlimited proliferation, (ii) evasion from growth suppressors, (iii) escape from the surveillance of the 
immune system, (iv) replicative immortality of cells, (v) escape from programmed cell death, (vi) 
dysregulated cell metabolism, (vii) DNA mutations/instability, (viii) dysregulated angiogenesis, (ix) 
escape from the primary tumor site and metastasis, and (x) a tumor promoting inflammation state 
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(Hanahan and Weinberg, 2011) (Fig. 3). It is possible to identify dominant hallmarks driving breast 
cancer heterogeneity by focusing on identified biomarkers and the associated subtypes. In particular, 
the extent to cells having ‘sustaining proliferative signalling’ is of particular importance in breast 
tumor classification, especially among hormone positive tumors such as ER, PR, and HER2 versus 
TNBC. Whereas, in tumors lacking hormone receptors, such as basal-like, other cancer hallmarks 
take a dominant role and are often associated with more aggressive properties, among these, 
“escaping from the primary tumor site and metastasis” is the most important. Another hallmark, 
“DNA mutations/instability” help to take into consideration some genomic amplification that occurs 
frequently in breast cancer, and that have predictive value. Finally, for breast tumors is emerging the 
hallmark “angiogenesis”, that we will analyse in this thesis work. 
 
 
Figure 3: Cancer hallmarks, adapted by (Hanahan and Weinberg, 2000, 2011) 
 
1.3.1 Hormone receptor status and the hallmark of “sustaining proliferative signalling” 
 
In normal cells, the proliferation event is severely controlled. Clearly the most fundamental trait of 
cancer cells involves their ability to sustain chronic proliferation. They carefully regulate the 
production and release of growth-promoting signals, maintaining the cell number and thus the tissue 
homeostasis. Cancer cells find the way to escape these growth signals and start to auto-maintain 
(Hanahan and Weinberg, 2011). Mutations in growth factors or their receptors could lead to an 
uncontrollable proliferation in cancer.  
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In breast cancer this hallmark has a crucial role especially in some subtypes such as Luminal A and 
B, and HER2-positive. Indeed, oestrogen and progesterone receptors act upstream a cascade of 
multiple growth-promoting signals which lead to the production of growth factors and their receptors 
and other signalling molecules that sustain cell proliferation and survival (Nicholson et al., 1999). 
Therefore, in patients that are ER and PR-positive it could act on limiting the hallmarks of 
proliferation by treating patients with hormone-interfering compounds (like Tamoxifen, Fulvestrant 
and aromatase inhibitors). Moreover, another mainstay factor in promoting breast cancer proliferation 
is epidermal growth factor receptor 2, HER2, a transmembrane growth factor receptor, that when 
overexpressed in breast epithelial cells causes the deregulation of G1/S control and leads to the 
upregulation of cyclin D1, E and cdk6, and degradation of p27 (Timms et al., 2002). In HER2 
overexpressing breast cancers, HER2-targeted therapies can be adopted, such as the monoclonal 
antibodies Trastuzumab and Pertuzumab. Furthermore, inhibitors of the CDK4/6 and mTOR 
pathways (such as Palbociclib and Everolimus, respectively) can be adopted (Manuscript under 
review). 
 
1.3.2 Breast cancer genomic amplification and the hallmark of “DNA mutations/instability” 
 
In addition to genomic amplification of HER2 that confers proliferative defects, it has been shown 
that breast cancer displays other amplification events, particularly in genes involved in DNA repair. 
The DNA repair system of normal cells is extremely efficient in detecting mutational events usually 
occurring. In cancer cells, the DNA mutations happens at a higher rate in comparison to normal cells, 
leading to genomic instability that fosters neoplastic transformation (Hanahan and Weinberg, 2011). 
By analysing breast tumours with fluorescence in situ hybridization and comparative genomic 
hybridization it has been found how breast tumours present a high number of genome copy number 
aberrations, such as amplification associated with adverse outcome. Commonly amplified sites 
include FGFR1, MYC, CCND1, MDM2, ERBB2 and ZNF217 gene loci (Chin et al., 2006). The 
degree of genomic instability influences the breast cancer patient’s prognosis (Auer et al., 1980, 
1984), as genomically unstable tumours are indicator of a shorter disease-free survival times 
compared to stable genome (Kronenwett et al., 2004, 2006). 
 
1.3.3 Basal-like breast cancers are characterized by the capacity of escaping from the primary tumor 
site and metastasize to other organs 
 
In advanced cancers stages or in particularly aggressive types of tumors, malignant cells can invade 
surrounding tissues or spread to distal organs, thus worsening the patient conditions. Among breast 
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cancer, the basal-like displays the most aggressive phenotype, in which hallmark like escaping from 
the primary tumor site and metastatization has a crucial role. In this subtype, the related deaths are 
more attributable to the metastatic spread of breast cancer cells rather than to the primary tumor itself 
(Weigelt et al., 2005). The metastatization is characterized by a cascade of events in which neoplastic 
cells lose some normal features such as the capacity of cell-to-cell adhesion and acquire new abilities 
to degrade the extracellular matrix and escape from the primary tumor site. In breast cancer a key 
event in this multistep process is the epithelial to mesenchymal transition (EMT), achieved by the 
loss of epithelial markers, like E-cadherin, and the expression of mesenchymal markers such as N-
cadherin, Vimentin and Fibronectin. Firstly, the alteration of cadherins expression, both the epithelial 
E- and mesenchymal N-types, causes the loss of adhesion capacity of cells to stromal cells and 
ultimately the stroma invasion by breast cancer cells (Cavallaro and Christofori, 2004). Beside this, 
in order to facilitate the tumoral cells invasion, the extracellular matrix has to be degraded: this 
process occurs thanks to metalloproteinases (MMPs) and the urokinase plasminogen activator system 
(uPA). In breast cancer context, it has been showed how uPA system has a prognostic importance in 
predicting the risk of distant metastases (Harbeck et al., 2004) and MMPs have been proved to 
mediate ECM proteolysis in invasive breast cancer cell lines (Kelly et al., 1998). Then, over-
expression of mesenchymal markers such as vimentin, that has emerged as an organizer of a number 
of critical proteins involved in attachment and migration, confers the ability to tumor cells to move 
and reach distal organs through the blood stream. The preferential sites of metastasis of breast cancer 
cells are bone and lungs, thanks to a chemokines gradient (Minn et al., 2005). Interestingly, in breast 
cancer low expression of E-cadherin is associates with a poor prognosis (Gould Rothberg and 
Bracken, 2006), and high levels of vimentin is associated with invasion and poor prognosis (Lehtinen 
et al., 2013). Moreover, vimentin expression was found higher in patients with stage IV breast cancer, 
underlying how it could be a significant biomarker for predicting reduced disease-free survival and 
overall-survival in breast cancer (Patel et al., 2015). As breast cancer tissue preferentially express 
CXCR4 receptor, the organs with a higher expression of its ligand CXCL12, such as lymph nodes, 
lung, liver and bone marrow, are common sites of breast cancer metastatic invasion (Bruce et al., 
1970). The cells detached from the primary or metastatic tumours which circulate in the blood vessels 
are called circulating tumor cells (CTCs) and they could indicate ongoing metastasis (Goodman et 
al., 2009). Moreover, the presence of CTCs above a certain cut-off predisposes the patients to a shorter 
progression-free survival and overall survival, highlighting the importance to evaluate this aspect 
(Consoli et al., 2011). In case of metastatic breast cancer, both standard chemotherapy and targeted 
therapies, such as hormonal and targeted treatments are adopted.  
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1.3.4 Tumor angiogenesis and breast cancer 
 
Since the first identification of the tight dependence of the tumour growing on the vascularization 
process, the interest in this issue has grown rapidly in the last years. The nutrients and oxygen supply 
to the tumour is a crucial step for cancer growth and metastatic dissemination. Indeed, a tumor mass 
can grow up to 2 mm without a vasculature network (Folkman, 1971). Once a tumor lesion exceeds 
a few millimetres in diameter, signals such as hypoxia and nutrient deprivation trigger the “angiogenic 
switch” to allow the tumor progression (Folkman and Hanahan, 1991).  In normal cells there is a 
balance between anti- and pro-angiogenic signals, balance that is then perturbed in tumoral cells. 
Malignant cells undergo the angiogenic switch favouring the production of pro-angiogenic molecules, 
event which in turn promote both primary tumor growth and a change from a quiescent to an invasive 
cancer phenotype (Kerbel, 2008). While in embryonic development the formation of new blood 
vessels initially occurs through de novo vasculogenesis from angioblasts, in tumor context vessels are 
formed from sprouting of pre-existing tubes and incorporation of endothelial progenitors into the 
growing vascular bed, event called angiogenesis (Rafii et al., 2002; Herbert and Stainier, 2011). This 
process involves the proliferation, migration and invasion of endothelial cells, their organization in 
functional tubular structures and moreover maturations and regression of vessels (Hicklin and Ellis, 
2005).  The new vasculature is characterized by abnormalities in its structure and function (Jain, 
1990), the blood vessels are immature and leaky (Tong et al., 2004). An increased tumor 
vascularization, in terms of microvessels density (MVD), has been widely connected to an advanced 
tumor stage and a poor prognosis, also in breast cancer: high MVD has been correlated with a shorter 
relapse-free survival and overall survival in patients with lymph node-negative breast cancer 
(Weidner et al., 1992). In this complex scenario, one factor and its downstream pathway have a 
predominant role in promoting tumor angiogenesis: the vascular endothelial growth factor (VEGF). 
VEGF belongs to a family of angiogenic and lymphoangiogenic growth factors which includes six 
secreted glycoproteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor 
PIGF -1 and -2. Specifically, VEGFA is one of the most important factor. Several isoforms of VEGFA 
are produced by alternative splicing of its gene, among those the VEGFA165 is the most abundant 
isoform (Giacca and Zacchigna, 2012). VEGF family members exert their role by binding several 
types of receptors on endothelial cells. Specifically, as represented in figure 4, VEGFA is secreted by 
cancer cells and, by binding VEGFR-2 on endothelial cells of the blood vessels, promotes their 
proliferation, migration and differentiation (Carmeliet and Jain, 2011) and thus the formation of new 
blood vessels from preexisting ones (Weis and Cheresh, 2011). Neurophilin (NRP) 1 functions as 
coreceptor for VEGF, lacking an intracellular signalling domain and enhancing the binding affinity 
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of VEGF ligands to their receptor (Soker et al., 1998). One of the most important process regulated 
by VEGFA is the vascular permeability, especially in tumor vessels. An increased permeability 
causes the leakage of several plasma proteins, a subsequent retardation in edema clearance from 
extravascular space and ultimately an activation of the stroma to a proangiogenic environment 
(Dvorak et al., 1995). Moreover, VEGF induces several other angiogenic properties, pivotal for the 
angiogenesis, such as the proliferation, invasion and migration abilities of endothelial cells, by 
regulating kinases ERK1/2 and uPA and tissue type plasminogen activator systems (Zachary and 
Gliki, 2001). Several works underline the importance of VEGF in breast cancer, in fact, high 
expression level of VEGFA has been indicated as an independent prognostic factor for relapse-free 
survival and overall survival specifically in lymph node-negative breast cancer patients (Manders et 
al., 2002). Moreover, a 13-gene VEGF signature has been demonstrated to predict poor outcome and 
distant metastases in breast cancer  (Hu et al., 2009), highlighting the link between VEGF and 
metastasis. In addition, high levels of VEGFR2 has been shown in a subset of TNBC and correlates 
with shorter survival (Rydén et al., 2010). Considering the dependence of the tumor progression on 
the angiogenic process and the pivotal role of VEGFA in promoting the tumor angiogenesis, it has 
been developed a monoclonal antibody, against this pathway, which specifically targets the activation 
of the VEGF receptor, bevacizumab. It has been reported that the use of anti-VEGF treatment is 
highly recommended in TNBC cases, which show high level of VEGFA (Greenberg and Rugo, 2010). 
Apart from bevacizumab, other antiangiogenic treatments are used against VEGF, such as the tyrosine 
kinase inhibitors sorafenib and sunitinib, which target VEGF receptors (Chung et al., 2010). 
Nevertheless, resistance mechanisms limit the long-term benefit of VEGF-targeted therapies: for 
instance, anti-VEGF therapy leads to the upregulation of placenta growth factor, which in turn binds 
to VEGFR1 and leads to the transphosphorylation of VEGFR2 (Loges et al., 2009). Therefore, 
studying molecular pathways that sustain pro-angiogenic properties is of paramount importance in 
order to discover new target therapies. 
 
 
 
                                                                                     Figure 4: Representation of angiogenesis induced by tumoral cells 
                                                                                                  on endothelial cells. 
                                                                                                 Adapted from Zhao and Adjei, 2015 
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2. HIGH MOBILITY GROUP PROTEINS 
 
The “High mobility group” (HMG) proteins are a group of non-histone architectural factors, pivotal 
for several cellular processes, such as embryonic development, DNA repair control, modulation of 
chromatin structure and above all the regulation of gene transcription (Cleynen and Van de Ven, 
2008; Reeves and Adair, 2005). They own their name to the high mobility in acidic (pH 2.4) 
polyacrylamide gel electrophoresis, as a consequence of their small molar mass (less than 30 KDa) 
in comparison with other nuclear proteins (Reeves and Wolffe, 1996). The HMG proteins can be 
subdivided in three different families, depending on the typical functional domain they possess: 
- HMGA family, characterized by three positively charged AT-hooks involved in the binding of 
Adenine and Thymine stretches on the minor groove of the DNA (considered as more than 4/5 A 
or T consecutive nucleotides); 
- HMGB family characterized by two alpha-helix HMG boxes which bind the non-B DNA form 
structures; 
- HMGN family containing a positively charged nucleosome binding domains that associate   with 
nucleosomes. 
My thesis will be focused on HMGA proteins family. 
  
2.1 HIGH MOBILITY GROUP A PROTEINS 
 
2.2.1 Structure of HMGA gene and protein 
 
As reported in figure 5, two different genes encode for the functional members of this family: 
HMGA1 gene, located at the chromosomal band 6p21, which produces two isoforms by alternative 
splicing, HMGA1a (107 aminoacid residues) and HMGA1b (96 amino-acid residues), differing for 
eleven aminoacid residues, and HMGA2 gene in 12q13-15 chromosome band from which the 
HMGA2 protein is produced (Fusco and Fedele, 2007). HMGA proteins display a natively disordered 
status, as they do not show any secondary or tertiary structures; nevertheless, by binding DNA or 
other proteins, HMGA proteins undergo several structural changes (Reeves, 2001) . This aspect gives 
HMGA proteins the possibility to interact with a multitude of molecular partners and thus regulate a 
variety of targets in a plethora of biological processes (Sgarra et al., 2010; Sumter et al., 2016). They 
possess three highly conserved palindromic basic amino acid motifs of proline-arginine-glycine-
arginine-proline, defined AT-hooks, through which they bind the AT stretches in the minor groove 
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of the DNA. Furthermore, they have an acidic carboxy-terminal tail, highly modified at post-
translational level, aspect that deeply impinges on HMGA activities (Sgarra et al., 2004).  
 
Figure 5: HMGA1 and -2 gene and protein structures. Adapted by Fusco and Fedele, 2007 
2.2.2 Molecular mechanisms of action 
 
As already described, HMGA proteins are chromatin architectural factors which do not display a 
transcriptionally activity per se; nevertheless, they are master regulator of the gene transcription, by 
their ability to bind both DNA and proteins, and assembling and/or modulating macromolecular 
complexes. Summarizing, they modulate transcription by acting through three different mechanisms. 
Firstly, HMGA proteins can interact with both DNA and proteins (Fig. 6a), thus forming 
macromolecular complexes, called enhanceosomes, on regulatory regions of their target genes, such 
as in the case of Interferon-Beta (IFN-β). In details, HMGA proteins bind and bend the DNA at the 
enhancer level of IFN- β gene promoter. HMGA1 binding enhances the binding affinity of other 
factors (c-JUN, ATF2 and NFκB) to the enhancer of IFN-β, thus regulating its transcription (Yie et 
al., 1999a). Secondly, it establishes direct protein-protein interactions (Fig. 6b), for instance with 
other transcription factors: among the plethora of factors bound by HMGA1, primarily it was found 
that NF-Y (Nuclear Transcription Factor) was directly bound by HMGA1, binding which enhances 
the affinity of NF-Y to its target (Currie, 1997); in addition, the SRF (Serum Response Factor) and 
HMGA1 collaboration positively regulate the c-FOS transcription (Chin et al., 1998). Moreover, it is 
noteworthy to mention the interaction between HMGA2 and pRB, which frees E2F1 from RB1 
binding and activates E2F1 transcriptional program (Fedele et al., 2006a). Finally, HMGA in general 
alter the chromatin structure (Fig. 6c), facilitating the accessibility of the transcription machinery to 
the DNA. Specifically, with their AT-hooks HMGA proteins are associated to matrix and scaffold 
associated region (MAR/SAR), DNA genomic region with high affinity for nuclear matrix. Moreover, 
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HMGA proteins compete with histone H1 for DNA binding, de-repressing the histone H1-mediated 
inhibition of SAR transcription (Zhao et al., 1993).  
Through these three different mechanisms of action, HMGA1 protein regulate a multitude of 
biological processes, such as cell growth, proliferation, differentiation and cell death (Cleynen and 
Van de Ven, 2008) and for this reason their expression level is tightly regulated during life.  
 
 
 
Figure 6: Mechanisms of action of HMGA proteins. a) HMGA proteins bind directly the DNA, altering the chromatin 
structure and facilitating the formation of the enhanceosome; b) HMGA proteins bind other transcription factors 
modifying their conformation and their DNA binding affinity; c) HMGA proteins alter the chromatin structure. Adapted 
by Fusco and Fedele, 2007 
 
2.2.3 Expression level of HMGA1 in physiological and pathological conditions 
 
HMGA1 proteins are highly expressed during embryonic stages when they take part in development 
as it has been demonstrated by in vivo mice through gene knockout. HMGA1 knock-out mice display 
myeloproliferative disorders and cardiac hypertrophy (Fedele et al., 2006b). Moreover, the double 
Hmga1/Hmga2 knock-out leads to the “super pygmy” feature with a reduced viability of embryos 
survived (Federico et al., 2014). In adult life, HMGA1 expression is very low or even absent  
(Chiappetta et al., 1996). Nevertheless, HMGA1 proteins are frequently re-expressed in cancer 
context. Overexpression of HMGA1 was first observed in HeLa S3 cells (Lund et al., 1983) and 
subsequently in cultured rat thyroid cells transformed by viral oncogenes (Giancotti et al., 1987). 
Since these discoveries the causal role of HMGA1 in cancer onset and progression has been 
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extensively studied during the years. Back to that observation, a high expression level of HMGA1 
proteins has been confirmed in many other tumor types, where HMGA1 overexpression correlates 
with a high malignant phenotype and a poor prognostic index (Fedele and Fusco, 2010). In addition, 
Pierantoni and colleagues demonstrated also the involvement of HMGA1 in several haematological 
leukemias, where HMGA1 high levels are reported (Pierantoni et al., 2003). Moreover, an axis 
between HMGA1 and STAT3, a pivotal player in cancer progression, has been established: indeed, 
HMGA1 positively regulates STAT3, found highly expressed in several haematological 
malignancies, by directly binding its promoter (Bowman et al., 2000).  
In the context of breast cancer, in 1993 Ram and colleagues found that the high expression level of 
HMGA1 correlates with the neoplastic transformation of mammary epithelial cells (Ram et al., 1993), 
induced to grow anchorage-independently and to form metastasis (Reeves et al., 2000). Moreover, 
the in vivo causal role of HMGA1 in breast cancer progression was studied in human breast epithelial 
cells MCF7 where the overexpression of HMGA1 transgene makes the cells able to form both primary 
and metastatic tumors in nude mice (Reeves, 2001). Years later, HMGA1 overexpression was also 
confirmed in 40% of hyperplastic lesions with cellular atypia and in 60% of ductal carcinoma, based 
on the analysis of breast cancer specimens (Chiappetta et al., 2004). As a confirm, a Gene expression-
based outcome (GOBO) for breast cancer online analysis highlighted an enrichment of HMGA1 
expression in basal and HER2 overexpressing breast cancer subtypes with respect to less aggressive 
subtypes, such as luminal A and B and normal-like (Pegoraro et al., 2013), thus connecting once again 
the HMGA1 not only to breast cancer but specifically to highly aggressive subtypes. HMGA1 has 
been tightly connected to several hallmarks of breast cancer. For instance, Baldassarre and colleagues 
demonstrated that the overexpression of HMGA1b in MCF7 cells induces a higher sensitivity to 
chemotherapy agents, such as cisplatin and bleomycin, enhancing the DNA damage predisposition 
of cells (Baldassarre et al., 2005). In addition, HMGA1 is also involved in cellular metabolism: 
indeed, by regulating the transcription of GLUT-3 (Ha et al., 2012) , which is a glucose carrier found 
at increasing doses during cancer progression (Kocdor et al., 2013) promotes the aggressive traits of 
invasive breast cancer. In metabolism context again, HMGA1 forms a multiprotein complex with Sp1 
and C/EBP-beta proteins on the promoter of the Insulin Receptor (INSR) (Foti et al., 2003), which is 
overexpressed in MCF7 and human breast cancer tissues (Paonessa et al., 2006).  In addition, in a 
triple negative breast cancer cell line model with a high proliferation and migration/invasion rates, 
the silencing of HMGA1 causes a reversion of the mesenchymal and less differentiated phenotype to 
a more polarized epithelial one: specifically, the depletion of HMGA1 brings the cancer cells to 
acquire an ordered monolayer sheet disposition, a reorganization of the cytoskeleton, decreases 
stemness and self-renewal ability. Moreover, it has a negative impact on the motility and the 
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invasiveness both in vitro and in vivo, and down-regulates a signature of genes related to epithelial to 
mesenchymal transition, stemness and poor prognosis (Pegoraro et al., 2013; Shah et al., 2013). 
Among the genes modulated by HMGA1, it has been found to regulate CCNE2 expression which in 
turn influences the nuclear localization of YAP and thus its malignant transcriptional program  
(Pegoraro et al., 2015). Furthermore, it has been demonstrated that HMGA1 modulates the expression 
level of SERPINE1 and PLAU, functional members of the Urokinase plasminogen activator system, 
involved in the promotion of the cellular migration and thus the metastatization process, through the 
remodelling of the extracellular matrix (Resmini et al., 2017).  
Regarding the cancer hallmark of angiogenesis, a few evidences report the role of HMGA1 in 
regulating this aspect, pivotal in physiological and pathological conditions. HMGA1 factor increases 
the VEGF transcription by directly binding its promoter, and this effect seems to occur synergistically 
in cooperation with HIF1, thus in hypoxic condition, in adipose tissue (Messineo et al., 2016). 
Moreover, HMGA1 has been discovered to regulate VEGFA and angiopoietin 1 expression in 
ischemic rat brains, promoting the viability of endothelial cells and consequently having a role in 
brain functions repair after a stroke event (Camós et al., 2014). Furthermore, in human gliomas a 
correlation has been established between HMGA1 and several other factors involved in cancer 
aggressiveness, among them VEGFA, suggesting a role for HMGA1 in angiogenic process (Pang et 
al., 2012). These studies highlight that HMGA1 is strictly involved at multiple levels in breast cancer 
aggressive features, regulating its progression and metastatic dissemination. 
Taken into consideration all these data, it appears clear that HMGA1 has a strong role in breast cancer 
aggressiveness acting on the majority of cancer hallmarks through the coordination of specific gene 
networks. Further dissecting the HMGA1–linked molecular mechanisms involved in breast cancer 
aggressiveness could give major chance of therapeutic intervention. 
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3. FOXM1 
 
3.1 Forkhead box family 
 
The Forkhead box M1 (FOXM1) protein belongs to the Forkhead box family of transcription factors. 
They are characterized by a highly conserved DNA binding domain of nearly 100 amino acids 
residues, the forkhead box (FKH) or “winged helix” domain at the N-terminal region, which assumes 
a helix-turn-helix structure, flanked by two loops called wings (Brennan, 1993). This large family of 
transcription factors comprises more than 100 proteins with temporally and spatially restricted 
biological functions, primarily involved in embryonic and adult homeostasis (Korver et al., 1997).  
 
3.2 FOXM1 structure and function 
 
The human forkhead box M1 gene is located on 12p13 chromosomal band and consists of 10 exons 
(Fig. 7). From the alternative splicing of two exons, exons Va (A1) and VIIa (A2), three different 
variants are produced: FOXM1a, in which both exons are present, FOXM1b with neither one the 
exons and FOXM1c in which only exon A1 is retained. FOXM1a is transcriptionally inactive, 
because of the insertion of the exon A2 in its transactivation domain, aspect which results in a 
dominant-negative variant without a functional transactivation domain (Ye et al., 1997), whereas both 
FOXM1b and FOXM1c are transcriptionally active (Korver et al., 1997; Ye et al., 1997). At the 
protein level FOXM1 is characterized by three domains: the FKH domain described above, which is 
involved in DNA binding; the transactivation domain (TAD) in its C-terminus, and the N-terminal 
repressor domain (NRD) involved in the autoregulatory activity of FOXM1. FOXM1 binds DNA in 
vitro preferentially to repeats of the consensus DNA motif TAAACA, highly conserved among the 
other Forkhead factors family members (Korver et al., 1997).  
FOXM1 regulates the transcription of several targets involved in paramount cellular activities. 
FOXM1 is intimately involved in the regulation of a transcriptional program of cell-cycle 
progression, such as G1-S and G2-M transitions, mitotic progression and the maintenance of 
chromosome stability, by regulating Skp1-Cullin 1-F box ubiquitine ligase complex, several cyclins 
(A2, B and D), Cdc25B, PLK1, Auroka kinases A and B, Survivin, and Centromere protein A, B and 
F whose promoters are directly bound by FOXM1  (Wang et al., 2005a, 2001, 2002). Indeed, 
FOXM1-depleted cells do not progress beyond the prophase stage of mitosis and they show cell-cycle 
abnormalities, such as delay in G2-M progression, chromosome missegregation and failure of 
25 
 
cytokinesis (Laoukili et al., 2005; Wang et al., 2005b; Wonsey and Follettie, 2005). Besides its central 
role in cell-cycle regulation, as transcription factor FOXM1 promotes also several other biological 
processes, such as stem-cell expansion and renewal, senescence and DNA-repair, epithelial to 
mesenchymal transition and angiogenesis, all functions important for embryonic and adult 
homeostasis  (Lam et al., 2013). Regarding vascular development, the importance of FOXM1 has 
been endorsed by in vivo FoxM1 knockout, in which the lungs of FOXM1 -/- mice show severe 
abnormalities of the lung vasculature concomitantly with reduced expression of Pecam-1 (Platelet 
endothelial cell adhesion molecule-1), the VEGF receptor type 1 (Flt1) and FoxF1, targets related to 
vasculogenesis (Kim et al., 2005). 
 
Figure 7: Structure of FOXM1 gene and proteins. Adapted by Laoukili et al., 2007 
 
3.2.1 Expression level regulation of FOXM1 
 
FOXM1 is defined as a proliferation associated factor, whose expression is tightly regulated during 
the cell cycle. Indeed, its expression level is high in proliferating cells, such as in embryonic cells, 
while it is negatively regulated in quiescent or terminally-differentiated cells. During adult life, 
FOXM1 expression is limited to highly proliferating and self-renewing cells, such as thymus, testis, 
small intestine and colon.  Nevertheless, FOXM1 is re-expressed when cells are induced to enter the 
cell cycle in response to mitogenic stimuli, tissue injury or oxidative stress (Korver et al., 1997; Yao 
et al., 1997). The importance of FOXM1 in embryonal stages is highlighted by FOXM1 knock-out 
mouse models, where heterozygous mutants appear normal, whereas the homozygotes die due to 
embryonal lethality. Occasionally, homozygous knock-out embryos complete the development but 
die after birth, because of severe heart defects, suggesting the important role of FOXM1 not only in 
embryogenesis but also during organogenesis  (Korver et al., 1998). Given the critical role of FOXM1 
in cell cycle progression, its expression is tightly regulated at different levels.  
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It has been demonstrated that FOXM1 is subjected to a strong post-translational regulation (Fig. 8). 
In fact, the cellular localization and transcriptional activity of FOXM1 is dependent upon its 
phosphorylation state: un-phosphorylated FOXM1 is located in the cytoplasm where it is inactive at 
late G1 and S phases (Ma et al., 2005), then it is phosphorylated by CyclinE-Cdk2 in G1 and it 
translocates into the nucleus; it is subjected to further phosphorylation events in a sequential order by 
several Cdk-cyclin complexes and mitogenic kinases in the S- and G2-M phases of the cell cycle, 
leading to the hyperphosporylated and completely active form of FOXM1 by the G2-M phases, 
Cyclin B-Cdk2 and Plk1. Several other post-translational modifications affect FOXM1 activity by 
controlling its protein levels. At the late M and G1 phases of the cell cycle FOXM1 is degraded after 
ubiquitination by the anaphase promoting complex/cyclosome complex (APC/C), in collaboration 
with Cdh1, (Park et al., 2008), leading to FOXM1 degradation. FOXM1 protein stability is also 
affected by sumoylation, which negatively regulates FOXM1 after its cytoplasmic translocation upon 
APC/C-Cdh1 induction (Myatt et al., 2014). At the transcriptional level, FOXM1 is principally 
controlled by three pivotal tumor suppressors Rb, p53 and p19ARF  (Jaiswal et al., 2014). Moreover, 
FOXM1 has a prominent role also on its own transcriptional activity. It has been highlighted that 
FOXM1 activates its own mRNA and protein expression in a positive feedback loop (Halasi and 
Gartel, 2009).  
 
 
 
 
Figure 8: Cell-cycle dependent regulation of FOXM1, adapted by (Laoukili et al., 2007) 
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3.2.2 FOXM1 and cancer 
 
Given a role in cell cycle, it is expected that FOXM1 plays a pivotal role in tumorigenesis. Indeed, 
elevated expression level of FOXM1 has been found in cancer context, implicated both at the early 
stages of carcinogenesis and in metastatic progression. The first identification of the causal role of 
FOXM1 in cancer came from a study of 2002, in which the authors demonstrated that this factor is 
up-regulated in basal cells carcinomas and that FOXM1 is a downstream target of Sonic Hedgehog 
pathway via GLI1 (Teh et al., 2002). Since that work, the awareness of the causal role of FOXM1 in 
cancer has grown intensively. Indeed, in 2004, a comparative microarray analysis unravelled FOXM1 
as one of the most commonly overexpressed gene in solid tumours, in particular in undifferentiated 
cancer with respect to well-differentiated types, strongly underline the importance of FOXM1 in 
cancer context (Pilarsky et al., 2004). Up-regulation of FOXM1 in neoplasias correlates with 
advanced tumour stage, high proliferation rate and a poor prognosis, bringing to light the possibility 
of using this factor as prognostic biomarker (Halasi and Gartel, 2009). Different mechanisms have 
been proposed to induce FOXM1 overexpression in cancer: (i) amplification of FOXM1 locus, which 
is frequently amplified in several cancers, among which we find breast cancer; (ii) an increase in 
FOXM1 protein stability and expression thanks to the interaction with other molecular partners, such 
as nucleophosmin; (iii) an enhancement of FOXM1 transcription, for example by Rb/E2F, cMyc and 
HIF1 which directly bind its promoter; (iv) mutations of p53 tumor suppressor and activation of 
FOXM1 by multiple signalling pathways, such as PI3/Akt, EGF receptor, Raf/MEK/MAPK and 
Hedgehog (Halasi and Gartel, 2009). As primarily implicated in cell-cycle regulation, the 
dysregulation of FOXM1 leads to an increase in cancer proliferation, thus in the early stages of 
tumorigenesis (Laoukili et al., 2007). Moreover, it increases the resistance of cancer cells to apoptosis 
(Koo et al., 2012). Indeed, Foxm1-transgenic mice develop larger tumors in comparison with their 
wild-type counterparts (Kalin et al., 2006). Furthermore, it is found implicated in other cancer 
hallmarks, indeed it promotes the migration, invasion and metastatic capabilities of cancer cells and 
the angiogenic process, promoting in this way more aggressive tumour traits. In this context, FOXM1 
is involved in the modulation of an EMT-transcriptional program. In particular, it up-regulates several 
EMT markers such as ZEB1 and 2, Snail 2, vimentin, fibronectin, N-cadherin and down-regulates E-
cadherin (Halasi and Gartel, 2009). It promotes also the expression of VEGF, by binding its promoter 
(Zhang et al., 2008). In addition, it modulates the extracellular matrix degradation by regulating 
MMP2 and MMP9 (Lim et al., 2009; Wang et al., 2007) and transcriptionally activates Stathmin, 
destabilizing the microtubules (Park et al., 2011), leading thus to an increased cancer cell invasiveness 
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and motility.  All these evidences reveal FOXM1 as a key player of cancer disease, highlighting how 
it is involved at multiple stages of cancer progression. 
 
3.2.3 FOXM1 and breast cancer 
 
Among the cancer tissues in which FOXM1 has been found up-regulated, it has been intensively 
connected to breast cancer. In a subset of breast cancer patients FOXM1 was associated to larger 
tumour size, lymphovascular invasion, lymph node metastases and higher stage of breast cancer (Ahn 
et al., 2015). In addition, overexpression of HER2 correlates with high level of FOXM1 mRNA 
(Bektas et al., 2008). Moreover, a whole genome and transcriptome sequencing of TNBC revealed a 
consistent overexpression of FOXM1 in this breast cancer subtype, suggesting a causal role of this 
factor. Altogether, these studies clearly show as FOXM1 has a prominent role in breast cancer and 
particularly in more aggressive subtypes. It exerts this tumor promoting role by modulating breast 
cancer at multiple levels. In particular, it is involved in the proliferation of malignant cells by binding 
the promoter and activating the transcription of Estrogen Receptor α, which in turn regulates FOXM1 
in a positive feedback loop (Madureira et al., 2006). In addition, this factor has a critical role in 
promoting drug resistance: by keeping p27kip1 expression low, it bypasses the Herceptin-induced G1 
arrest (Carr et al., 2010). It up-regulates anti-apoptotic genes, such as XIAP and Survivin, contributing 
to chemoresistance (Nestal de Moraes et al., 2015). Furthermore, FOXM1 enhances DNA repair, thus 
leading to resistance to cisplatin and epirubicin in breast cancer cells (Kwok et al., 2010; Millour et 
al., 2011). FOXM1 has a role also in promoting EMT and metastatization processes: it binds the 
promoter of SLUG (Yang et al., 2013) and by interacting with SMAD3 and stabilizing the SMAD3/4 
complex activates the TGF-beta pathway (Xue et al., 2014), modulating in this way a crucial 
oncogenic pathway. Given the previously described central role of angiogenesis in the growth, 
progression and metastasis of solid tumors such as breast tumors, it is of interest to underline the 
involvement of FOXM1 in the direct binding and transcription of the VEGF promoter by competing 
with another Forkhead member, FOXO3A, in breast cancer cell lines (Karadedou et al., 2012).  
From these evidences it is obvious that a deregulation of FOXM1 has a causal role in triggering and 
fostering breast and other types of cancer. Indeed, it is considered a strong candidate biomarker for 
cancer and several anti-cancer drugs directly and indirectly targeting FOXM1 have been tried, such 
as proteasome inhibitors, which negatively regulate this factor. Nevertheless, much effort has to be 
made to better elucidate how to target FOXM1, a paramount factor for breast cancer progression. 
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Triple negative breast cancer (TNBC) is one of the most aggressive and less curable subtype of 
cancer, lacking specific treatments, aspect that motivates researchers to deepen the factors strictly 
responsible for the aggressive traits of this disease. Among the factors involved in TNBC progression, 
HMGA1 has been strongly connected to malignant features of breast cancer, for its plasticity as 
architecture proteins in controlling many cellular processes by associating with other factors. Thus, 
to better address TNBC treatments, further exploring the network HMGA1 play a role in could be of 
extreme interest. The purpose of this work is to unravel new molecular partners of HMGA1 and better 
investigate their synergistical action in controlling common pathways promoting several cancer 
hallmarks. To achieve this objective, we took advantage of cellular models of triple negative breast 
cancer overexpressing HMGA1 and we deepened the features controlled by its interaction with new 
molecular partners.  
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Materials and Methods 
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1. Cell Culture  
 
The human triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-157 and the human 
embryonic kidney cell line HEK293T were routinely grown in high glucose Dulbecco’s Modified 
Eagle Medium (DMEM, Euroclone), with 10% tetracycline-free Foetal Bovine Serum (FBS, 
Euroclone), 2mM L-Glutamine (Euroclone), 100 U/ml Penicillin (Euroclone), 100 µg/ml 
Streptomycin (Euroclone). For routine cell culture passage, cells were dissociated with Trypsin-
EDTA (0.05% trypsin, 0.02% EDTA in PBS, Euroclone). For long-term maintenance, cells were 
collected in FBS 10% (v/v) DMSO (AnalaR BDH) and stored in liquid nitrogen. 
 
2. siRNA Transfection 
 
The day before the siRNA transfection, cells were seeded in antibiotics-free DMEM at a density of 
2*105 cells/35-mm dish (Corning). The LipofectamineTM RNAimax reagent (Invitrogen/Thermo 
Fisher Scientific) was used for transfection of 30 pmol of siRNA/35-mm dish, following the 
manufacturer instructions. For co-silencing experiments, 30 pmol of each specific siRNA and 60 
pmol of siCTRL in the control condition were transfected. The cells were processed after 72 hours of 
silencing. 
siRNAs used in this work are listed in the following table: 
 
TARGET GENE siRNA SEQUENCE (5’-3’) 
 siCTRL ACAGUCGCGUUUGCGACUG 
HMGA1 a/b siA1_3 ACUGGAGAAGGAGGAAGAG 
FOXM1 siFOXM1 CCUUUCCCUGCACGACAUG 
 
3. Plasmid transfection 
 
Plasmid transfections were carried out using Lipofectamine 3000 (Invitrogen/ThermoFisher 
Scientific), following the manufacturer protocols, for MDA-MB-231 cells and the standard Calcium 
Phosphate transfection method for HEK293T cells. For overexpression experiments, 35*104 cells 
were seeded in 35 mm diameter dish the day before the transfection.   
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The plasmids transfected are listed below: 
• pEGFP-N1, pEGFP-N1 HMGA1a, pRL-CMV Renilla (Promega) and pGL4.11 (Promega) were 
already present in the laboratory. 
• pEGFP-FOXM1 and pGL3-5BS (containing five repetitions of FOXM1 binding sites-
TAAACA) were kind gifts of Dr. Muy Teck Teh from the Department of Diagnostic and Oral 
Sciences, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen 
Mary University of London, London, UK. 
• The vectors used in this work named pGL4.10-VEGFprom (-1000-1), pGL4.10-VEGFprom (-
1000-500), pGL4.10-VEGFprom (-500-1), as they contain a portion of the VEGFA promoter 
that goes from -1000 to -1 bp, -1000-500 bp and -500-1 bp respectively, were a gift from David 
Mu (Addgene plasmid # 66128, # 66129, #66130). 
• The deletion mutants pGL4.10-VEGFpromWT(-388-1), pGL4.10-VEGFprom (-338-1), 
pGL4.10-VEGFprom (-172-1) and the pGL4.10-VEGFprom (-104-1), containing a region of the 
VEGFA promoter spanning from -388-1 bp, -338-1 bp, -172-1 bp, and -104-1 bp respectively, 
were generated in the laboratory by amplifying the pGL4.10-VEGFprom (-1000-1) with the 
forward primers 5’-GGGGTACCCCGGGGCGGGCCGGGGGCGGGGTCC-3’,5’- 
GGGGTACCCCCTTTTTTTTTTAAAAGTCGGC-3’,  5’- 
GGGGTACCTGGAATTTGATATTCATTGATCCG -3', 5’- 
GGGGTACCTGTATTGTTTCTC GTTTTAATTT- 3’ for the -388, -338, -172 and -104 to -1 
bp fragments respectively and the common reverse primer 5’- 
CCCAAGCTTAAAATCCACAGTGATTTGGGGAA - 3’. We then created a pGL4.10-
VEGFpromMUT(-388-1) mutated in two SP1 binding sites (GGGCGG  GGAAGG) by 
amplifying the pGL4.10-VEGFprom (-1000-1) with the forward primer 5’- 
GGGGTACCCCGGGAAGGGCCGGGGAAGGGG TCC -3’ (GC  AA) and the reverse 
primer used in previous experiments.  
Subsequently, the PCR products were cloned in KPNI and HINDIII (Amersham Biosciences) 
restriction sites of pGL4.11 vector. All the plasmids generated in the laboratory were sequenced 
by Eurofins Genomics sequencing service.  
 
In particular, for immunofluorescence experiment upon HMGA1 silencing in HEK293T cells, one 
day after the silencing we transfected 1 µg of pEGFP-FOXM1.  
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For luciferase reporter assays, a total amount of 1.4 µg of plasmid DNA was transfected in HEK293T 
cells by Calcium Phosphate method. Specifically, we used the following amounts of plasmids: 
- 200 ng of the Luciferase reporter, specific for each experiment; 
- 1200 ng of pEGFP-N1 in the control condition; 
- 600 ng of pEGFP-N1 HMGA1a or/and 600 ng pEGFP-FOXM1. 
The luciferase assay was also carried out upon silencing condition, in which the expression of 
HMGA1 or FOXM1 was knocked down by transfecting 30 pmol of siRNA/35-mm dish, followed by 
the transfection of 1 µg of DNA, as follows: 
- 200 ng of the Luciferase reporter, specific for each experiment 
- 1000 ng of pEGFP-N1 in the control condition 
- 600 ng of pEGFP-N1 HMGA1a or 600 ng pEGFP-FOXM1 
For each condition, 10 ng of pRL-CMV Renilla was transfected. Renilla luciferase was used as 
normalizer. 
4. Luciferase assay 
 
The Dual-Luciferase® Reporter Assay System (Promega) was used for the luciferase reporter assay, 
following the manufacturer instructions. The measurements were carried out using the Berthold 
Lumat LB 9501 Tube Luminometer; two technical replicates were performed for each sample. As 
HMGA1 is insoluble in the Passive Lysis Buffer provided by the Promega Dual-Luciferase kit, we 
centrifuged 1/5 of the total volume of cells collected in PBS1X for 5 minutes at 200 g and the cells 
were lysed in 20 µl of SDS sample buffer. The amount of proteins transfected was checked by 
Western blot analysis. 
5. Protein extraction and western blot analysis 
 
Cells were washed in ice-cold PBS1X and then were lysed in SDS sample buffer (62.5 mM Tris, pH 
6.8; 2% SDS; 10% glycerol) with 200 mM DTT, 1 mM Na3VO4, 5 mM NaF and mammalian protease 
inhibitor cocktail (PIC) (Sigma). Afterwards, DNA were disrupted with passing the sample through 
an insulin syringe and boiled for 5 minutes. Total lysates were separated by SDS-Polyacrylammide 
gel electrophoresis (SDS-PAGE) in SDS-PAGE gel composed by the stacking and the running gel: 
Stacking gel: 5%: 5% acrylamide/bisacrylamide (29:1), 0.125 M Tris-HCl pH 6.8, 0.1% (w/v) SDS, 
0.05% (w/v) APS and 0.05% (v/v) TEMED. Running gel: 7.5%: 7.5% acrylamide/bisacrylamide 
(29:1), 0.3 M Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.05% (w/v) APS and 0.05% (v/v) TEMED; 10%: 
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10% acrylamide/bisacrylamide (29:1), 0.5 M Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.05% (w/v) APS 
and 0.05% (v/v) TEMED; 15%: 15% acrylamide/bisacrylamide (29:1), 0.375 M Tris-HCl pH 8.8, 
0.1% (w/v) SDS, 0.05% (w/v) APS and 0.05% (v/v) TEMED. Gel thickness: 0.75 mm, length of 
stacking gel: 0.5 cm, length of running gel: 8 cm, gel width: 8 cm. The electrophoresis was carried 
out in running buffer composed by 25 mM Tris, 200 mM Glycine, 3.5 mM SDS (w/v) and performed 
at 50V for the accumulation step and then at 200V for the protein separation, till the complete 
separation of the molecular markers (Pre Stand, Thermo Fisher Scientific). Subsequently, the gel 
could be stained in solution of methanol/water/acetic acid solution (in a volume ratio of 5/4/1) 
containing 0.05% (w/v) Coomassie Brilliant Blue R 250, and then destained in a solution of 10% 
Acetic Acid in H2O, in order to perform the protein quantification. Alternatively, the proteins were 
transferred to nitrocellulose membrane ∅ 0.2 μm (GE Healthcare, WhatmanTM) using a wet transfer 
system (Transfer buffer: 25 mM Tris, 200 mM Glycine, 20% methanol) at 4°C for 16 hours at 40 V. 
After the transfer step, membranes were then stained with Red Ponceau solution (0.2% red ponceau 
S, 3% trichloroacetic acid, 3% sulfosalicylic acid). Western blot analyses were performed according 
to standard procedures. To revealed horseradish peroxidase conjugated to secondary antibody on 
autoradiography films (GE Healthcare), Liteablot Extend ECL (Euroclone) or TPro Lumilong Plus 
(T-Pro Biotechnology) were used. 
 
The antibodies used are listed in the following table: 
Primary Antibody Antibody diluition 
αHMGA1 (made in the laboratory) 1:500 
αFOXM1 (A301-533A-M, Bethyl Laboratories) 1:700 
αGFP (kind gift of Professor Collavin, LNCIB, Trieste) 1:1000 
α-β-actin (A2055, Sigma) 1:2000 
 
Secondary Antibody Antibody diluition 
α-rabbit IgG peroxidase conjugate 
(A0545, Sigma) 
1:5000 (1:2500 for αFOXM1) 
α-mouse peroxidase conjugate 
(A9044, Sigma) 
1:5000 
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6. Migration Assay 
 
For wound healing assay, MDA-MB-231 cells were seeded in antibiotics-free DMEM at a density of 
2*105 cells/well in a 6-multiwell dish (Corning) in biological triplicates and were silenced for 
HMGA1 and/or FOXM1 as previously described. The cells were cultured to 90% confluence and 
then scraped with a 200-μl tip, and wound closure was followed for 7 hours. Two images for the same 
area were taken for each well.  
 
7. Immunofluorescence 
 
Cells were grown on glass coverslips and treated for each experiment; they were then washed in 
PBS1X and fixed in a solution of PBS 1X 4% Paraformaldehyde (pH 7.2). Cells were incubated with 
a solution of PBS1X with 0,1 M Glycine (Sigma-Aldrich/Merck) in order to reduce autofluorescence 
background and then incubated with PBS1X 0.3% Triton 100X (Sigma-Aldrich/Merck) to 
permeabilize cells. Between each passage, the cells were washed three times in PBS1X. We then 
proceeded with a 45 minutes blocking step with a blocking solution of PBS1X 5% Bovine Serum 
Albumin (BSA-Sigma-Aldrich/Merck). Subsequently, we incubated with the appropriate primary 
antibody diluted in blocking solution added with 0.01% Triton for 90 minutes in a wet environment; 
we washed the cells in PBS1X and we incubated the cells with the secondary antibody in PBS1X for 
45 minutes. We washed the cells in PBS1X, incubated them in a solution of PBS1X 1:1000 Hoescht 
to detect nuclei and finally we mounted the coverslips on glass supports with the Vectashield 
mounting medium (Vector Laboratories).  
The primary and secondary antibodies used in this project are enumerated in the following table:  
Primary antibody Dilution 
αHMGA1 (made in the laboratory) 1:50 
αFOXM1 (rabbit-Bethyl) 1:100 
αVIMENTIN  (mouse-Dako) 1:200 
 
Secondary antibody Dilution 
α-rabbit IgG Alexa 594 (Thermo 
Fisher Scientific) 
1:500 
α-mouse IgG Alexa 488 
(Thermo Fisher Scientific) 
1:500 
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The images were visualized using a Nikon Eclipse e800 microscope and acquired using Nikon 
ACT-1 software, then analysed by the ImageJ software analyser.  
8. RNA extraction 
 
Cells were washed in ice-cold PBS1X and lysed in 1 ml of TRIzol (Thermo Fisher Scientific). Total 
RNA was isolated following the manufacturer’s instructions of the TRIzol reagent and resuspended 
in UltraPure™ DNase/RNase-Free Distilled Water (Thermo Fisher Scientific). The isolated RNA 
was subjected to DNase-I (Deoxyribonuclease I Amplification Grade, Invitrogen) treatment as 
indicated in the datasheet and to a subsequent phenol/chloroform purification. The RNA quality was 
checked by running an aliquot of the RNA on a denaturing agarose gel MOPS 1% (w/v) agarose 
(Sigma), 6.67% (v/v) formaldehyde (Sigma) in MOPS buffer (20 mM MOPS, 5 mM sodium acetate, 
1 mM EDTA, pH 7). In addition, RNA was quantified at NanoDrop 2000 (ThermoFisher Scientific). 
9. Gene expression analysis  
 
1 g of total RNA was reverse transcribed with Random primer by the Superscript III (Invitrogen), 
according to the manufacturer's instructions. The quantitative RT-PCR (qRT-PCR) was carried out 
using diluted cDNA combined with iQTM SYBR Green Supermix (BIO-RAD) and specific primers 
listed below. The reaction was performed in technical duplicates. The PCR reaction was performed 
in BIO-RAD CFX instrument and the protocol used was the following: an activation step at 95°C for 
3 minutes followed by 40 cycles of a denaturation step at 95°C for 5 seconds and an amplification 
and elongation step at 60°C for 30 seconds. The data obtained were analysed with BIO-RAD CFX 
Manager software and the relative gene expression was calculated by ΔΔCt method, using the 
GAPDH as a normalizer. The genes evaluated in qRT-PCR are enumerated below with the primer 
sequence used: 
 
Target gene/primer 
name 
 
Forward primer (5’- 3’) Reverse Primer (5’- 3’) 
hGAPDH TCTCTGCTCCTCCTGTTC GCCCAATACGACCAAATCC 
hHMGA1/HMGA-
3’UTR 
ACCAGCGCCAAATGTTCATCCTCA AGCCCCTCTTCCCCACAAAGAT 
hFOXM1  AGAAACGACCGAATCCAGAGC CTGACCCGTGGTAGCAGTG 
hVEGFA AGGAGGGCAGAATCATCACG ACCAGGGTCTCGATTGGATG 
hCCNE2 TGAGCCGAGCGGTAGCTGGT GGGCTGGGGCTGCTGCTTAG 
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hLEF1 CGAATGTCGTTGCTGAGTGT GCTGTCTTTCTTTCCGTGCT 
hSNAI2/SLUG TTCGGACCCACACATTACCTTG AGGGCAAGAAAAAGGCTTCTCC 
 
10. Preparation of MDA-MB-231 samples for RNA-Sequencing  
 
MDA-MB-231 cells were silenced for HMGA1 and the RNA were collected at 24 and 72 hours after 
the silencing. Three biological replicates were made for each condition. The total RNA was then 
extracted and checked as described above. Then, an aliquot of RNA was reverse transcribed and the 
silencing of HMGA1 was confirmed by qRT-PCR. The RNA-Sequencing was performed in San 
Raffaele Institute, Milano. 
11. RNA-Sequencing analysis  
 
Demultiplexed raw reads (fastq) generated from the Illumina HiSeq were check using FASTQC tool 
(Version 0.11.3). All samples passed the quality standards. Then we aligned to the reference genome 
(UCSC-hg19) using STAR (Dobin et al., 2013), version 2.0.1a using recommended options and 
thresholds.  HTSeq-count (version 0.6.1) was used to generate gene counts. Starting from read counts, 
differential gene expression analysis was performed using EdgeR (version 1.10.1, R version: 
3.2.3,(Robinson et al., 2010), comparing the different time points using a quantile-adjusted 
conditional maximum likelihood (qCML) method. In order to identify the relationship between each 
sample and every other sample, the Euclidean distance between each pair of samples was calculated 
using the log-transformed values of the complete data set. Average linkage clustering was then used 
to generate a sample-to-sample distance heatmap, via the cluster3 package (Cluster3: 
http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm#ctv). For statistical analyses the 
adjusted p-values were generated via the Benjamini-Hochberg procedure. Finally, genes were 
selected as differentials with a cutoff of 0.5 for the log Fold change and 0.05 for the False Discovery 
Rate.  
Differentially expressed genes were analysed using Ingenuity Pathway Analysis (IPA, Ingenuity® 
Systems, www.ingenuity.com). The prediction of the transcription factors and regulative molecules 
was obtained using the Upstream regulators function (IPA suite). For every upstream regulator an 
overlap p-value and a z-score are calculated: the p-value indicates the significance based on the 
overlap between dataset genes and known targets regulated by the molecule, while the z-score is used 
to infer the possible activation (z-score ≥ 1,8) or inhibition (z-score ≤ -1,8) of the molecule based on 
prior knowledge stored in the proprietary Ingenuity Knowledge Base. 
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All statistical test and calculation have been performed in R (Dean and Nielsen, 2007) environment.  
12. Preparation of the Condition medium (CM) for Angiogenic assays 
 
MDA-MB-231 were seeded and silenced for HMGA1 and/or FOXM1 as described. The day before 
proceeding to the collection of the cellular supernatant, the cells were washed and cultured with 
serum-free DMEM. After 72 hours of silencing, the condition medium was collected, centrifuged at 
240Xg at 4°C for 5 minutes to deposit cells debris and stored at -80°C. The cells were then washed 
in PBS 1X and lysed in SDS sample buffer as described. The HMGA1 and FOXM1 protein levels 
were checked by Western blot analysis.  
13. Endothelial cells Proliferation analysis 
 
Endothelial cells HUVEC were seeded in 96 well plate, 5000 cells/well.  The cells were incubated 
with HMGA1, FOXM1 and HMGA1/FOXM1 condition medium and the control medium for 18 
hours. Normal Horse serum 10% was used as positive control. After a washing step, the cells were 
detached from the wells with trypsin/EDTA (Sigma-Aldrich), seeded on a slide, and fixed first with 
4% paraformaldehyde (Sigma-Aldrich) for 1 hour and then with cold methanol for 15 minutes. After 
two runs in microwaves in Tris/EDTA solution and washing with PBS, the cells were incubated with 
the anti-Ki-67 antibody (Dako) 1:75 in permeabilization solution, 30 minutes at room temperature. 
After two washing steps, we incubated with the secondary antibody anti-mouse FITC (Dako) 1:50 in 
permeabilization solution 50 minutes at room temperature. The cells were washed twice and lysed. 
Measurements were performed in TECAN 480-535nm (gain 70).   
14. Transwell migration assay of endothelial cells 
 
150000 cell/well of endothelial cells HUVEC CA3 (passage 2) were seeded in 200 μl of DMEM 
serum free medium (Invitrogen) in the upper compartment of 8 μm pore 24 transwell plate, pre-coated 
with human Fibronectin (Sacco) in the lower face. We proceeded by incubating the cells with 500 µl 
of HMGA1 and/or FOXM1 CMs, and with serum free medium as a negative control or Normal Horse 
Serum 10% (NHS) as a positive control in the lower compartment of the transwell. After 18 hours of 
incubation, the cells were lysed with lyses buffer for Coulter and the number of migrated cells were 
counted with Coulter Counter BD. 
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15. In vitro tube formation of endothelial cells 
 
5.5*104 of HUVEC endothelial cells were plated on wells precoated with Matrigel (12µg/ml) 
(Becton Dickinson) and incubated for 18 hours with CMs diluted 1:2, with 20 ng/ml VEGF as a 
positive control or with serum-free medium as a negative control. After 4% paraformaldehyde 
fixation step and staining with Phalloidin-Alexa Fluor 546 (Invitrogen), the number of tubules was 
counted under a Leica AF6500 microscope using LAS software (Leica).  
16. Preparation of cells for Zebrafish injection 
 
1.2*106 of  MDA-MB-231 cells were cultured and co-silenced for HMGA1 and FOXM1 as described 
before. After 40 hours of silencing the cells were injected in the yolk sack of Zebrafish embryos.  
17. Zebrafish Xenograft 
 
Zebrafish were raised and maintained as previously described (Tonon et al., 2016). Embryos were 
generated by natural pair-wise mating and were kept and handled for all experiments in E3 medium 
(5 mM NaCl, 0.17 mM KCl, 0.33mM CaCl2, 0.33nM MgSO4) and PTU (1-phenyl 2-thiourea, 0.03 
mg/ml) to reduce zebrafish skin pigmentation for microscope analysis. All experimental procedures 
were conformed to the ITA guidelines (Dgl 26/2014) in accordance with EU legislation 
(2010/63/UE); this protocol was approved by the Ethics Committee for Animal Experimentation 
(OPBA) of the University of Trieste (Protocol number PO1937ZEN16). In this study, the 
Tg(fli1:EGFP) (y1) Zebrafish larvae were used. This transgenic fluorescent strain expresses in the 
entire vasculature EGFP under the control of the fli1 promoter (Delov et al., 2014). Before all 
experimental procedures, animals were properly anesthetized by using 1:100 dilution of 4 mg/ml 
Tricaine (Sigma-Aldrich Co., St Louis, MO, USA). Two days post fertilization (2dpf), Zebraﬁsh 
embryos were dechorionated and microinjected with MDA-MB-231 siCTRL and siHMGA1/FOXM1 
cell lines or cellular medium alone as control. Each cells suspension was stained by 2 µg/ml DiI 
(Sigma Aldrich) for 10 min at 37°C, re-suspended in DMEM medium and kept on ice before injection. 
Microinjections were performed with the electronic FemtoJet microinjector (Eppendorf) using 
borosilicate glass micro-capillaries (20 mm O.D. 15 mm I.D.; Eppendorf). Approximately 500 cells 
were microinjected into the yolk of each embryos, which were then maintained in E3 medium/PTU 
for 1 hour at 28°C. Afterwards embryos were kept at 34°C to allow tumor cells survival and growth 
as previously described (Jung et al., 2012). 24 hours after microinjection, the larvae were observed 
under fluorescence microscope (Leica DM 2000). During all the procedures live animals, properly 
anesthetized, were positioned in 1.5% methylcellulose (Sigma Aldrich Co). The images of the tumor 
41 
 
masses were acquired in red signal (DiI staining) and then merged with the respective bright field 
image by using the Leica Application Suite X (LAS X) software. Instead, to evaluate the host 
angiogenic response to the injected tumor cells, vessels images were acquired in green (GFP) signal 
and then analyzed using the ImageJ software. For both analysis, 22 animals for each cell line, divided 
into two independent experiments, were considered. 
For gene expression, total RNA was extracted from at least 15 larvae for each experiment using Trizol 
Reagent (Invitrogen, Life Technologies, Milan, Italy). RNA concentration was determined by 
Nanoquant (Tecan). One µg of total RNA was reverse transcribed using M-MLV reverse transcriptase 
(Life Technologies). Gene expression was analyzed by real-time quantitative RT-PCR (Step One 
Plus, Applied Biosystems) using the SYBR Green system (Life Technologies). The primer sequences 
are listed below. The gene analysis was repeated twice and the values were normalized respect to 
medium treated animals. 
  Target 
gene/primer 
name 
Forward primer (5’-3’) Reverse Primer (5’-3’) 
zVEGFA 
(Zebrafish 
VEGFA) 
GATGTGATTCCCTTCATGGATGTGT GGATACTCCTGGATGATGTCTACCA 
zFLT-1 
(zebrafish 
VEGF 
receptor 1) 
AACTCACAGACCAGTGAACAAGATC GCCCTGTAACGTGTGCACTAAA 
zFLK-1 
(zebrafish 
VEGF 
receptor 2 
GACCATAAAACAAGTGAGGCAGAAG CTCCTGGTTTGACAGAGCGATA 
zACTIN  
(zebrafish 
actin) 
CAGCAAGCAGGAGTACGATGAGT TTGAATCTCATTGCTAGGCCATT 
hKi67  
(human 
Ki67) 
GCCTGCTCGACCCTACAGA GCTTGTCAACTGCGGTTGC 
hGAPDH  
(human 
GAPDH) 
CCCATCACCATCTTCCAGGAG CTTCTCCATGGTGGTGAAGACG 
42 
 
18. Statistical Analysis 
Data were analysed by a two-tailed Student’s t test, and results were considered significant at a p-
value <0.05. The results are presented as the mean and standard deviation (±SD). Specifically, a p-
value<0.05 is indicated with *, a p-value<0.01 with ** and a p-value<0.001 with ***.   
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Results 
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1. A bioinformatic analysis reveals FOXM1 as a putative molecular partner of HMGA1 
 
HMGA1 has been widely proved to be involved in breast cancer progression and, given its 
mechanisms of action as architectural transcription factor, it is clearly engaged in the regulation of 
several gene networks where it exerts its activity by cooperating with a broad spectrum of 
transcription factors. In order to better unravel the yet unexplored pathways controlled by HMGA1 
in regulating several malignant aspects of the highly aggressive triple negative breast cancer subtype, 
we performed a deep RNA-Sequencing analysis of our model of TNBC, the MDA-MB-231 cells, at 
24 and 72 hours following HMGA1 silencing. From the sequencing analysis, we were interested in 
discovering new transcriptional molecular partners of HMGA1, therefore, we proceeded with three 
steps: 1. identification of differentially expressed genes (DEG) upon HMGA1 silencing; 2. analysis 
of gene networks DEG are involved in; 3. prediction of transcription factors regulating these gene 
networks (Fig. 1). 
 
Figure 1: A bioinformatic analysis on HMGA1-silenced MDA-MB-231 cells reveals new molecular partners of HMGA1 
in regulating downstream gene networks. At 24 and 72 hours of silencing, the RNA was collected and subjected to deep RNA 
sequencing. From the data, differentially expressed genes (DEG) were identified, and their pathways were rebuilt by Ingenuity Software 
analysis. Among the different upstream factors controlling these pathways, we focused on transcription factors, putative HMGA1 
molecular partners in regulating the identified gene networks in triple negative breast cancer. 
 
In collaboration with the Bioinformatic unit of LNCIB (Trieste), we found out, as first thing, the 
transcripts whose expression changed upon HMGA1 depletion on the different time points. Then, we 
proceeded by analysing these DEG with the Ingenuity Pathway software (IPA). This tool crosses the 
gene expression changes observed with known datasets collected from literature data to build up the 
gene networks these DEG are included in. We then focused on the hub of these networks, and we 
found that they could be governed by different upstream regulators, such as transmembrane receptors, 
transcription factors and co-activators/repressors, and compounds.  
Among these identified upstream regulators, we focused our attention on transcription factors, as they 
could be putative molecular partners of HMGA1 in regulating the networks these DEG are involved 
45 
 
in. The upstream factors were then sorted by p-value which is a measure of how much the overlap 
between their known dataset and our HMGA1-modulated gene list is significant. Moreover, they were 
ranked according to a Z-score which is an indicator of the state of activation/inhibition of gene 
networks in the presence of activity of the transcription factors we identified as hub. A positive Z-
score means an activation state of the downstream network in common between a transcription factor 
and HMGA1, network which in turn was negatively regulated after HMGA1 silencing. The first five 
upstream regulators with a Z-score of ≤ -18 or ≥ 1.8, that we chose as a cut off, in at least one-time 
point, are listed in table 1.  
 
 
 
 
 
 
Table 1: Several known and unknown HMGA1 partner were obtained by the bioinformatic analysis on TNBC 
cells. The transcription factors listed, putative molecular partners of HMGA1, were ranked by their pvalue24h. 
 
Interestingly, with this bioinformatics analysis we found well known transcriptional partners of 
HMGA1, reinforcing the robustness of our bioinformatic method. In fact, the role of HMGA1 
together with STAT3, E2F and RB1 in regulating gene expression has been already explored (Hillion 
et al., 2008; Ueda et al., 2007). We decided to focus on FOXM1, both for its Z-score values, which 
increases between the two time-points, and for the well-known role of this factor in breast cancer 
(Saba et al., 2016). The IPA outcome of FOXM1 as hub upstream regulator is represented in figure 
2 and target genes of the downstream network in common between FOXM1 and HMGA1 at 24 and 
72 hours after HMGA1 silencing are listed in tables 2a and 2b.  
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Figure 2: Ingenuity pathway analysis outcome of FOXM1. At the centre, we find the upstream regulator (FOXM1) 
of the pathways (connected-factors) found activated or inhibited by HMGA1, predicted to be in common with FOXM1, 
hub of this network.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Several HMGA1 differentially expressed genes (DEG) promoting breast cancer aggressive traits 
belong also to the FOXM1 network. The 24 hours targets are listed in panel a, while the data referred to the 72 hours 
HMGA1 silencing are listed on the table in panel b. 
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From these data, we hypothesized that HMGA1 could cooperate with FOXM1 in regulating specific 
gene networks that modulate crucial cancer hallmarks in conferring breast cancer aggressiveness. In 
support of the bioinformatic analysis, we took advantage of The Cancer Genome Atlas (TCGA) data, 
a public database collecting information from a high number of cancer patients obtained from high-
throughput approaches, searching for a connection between HMGA1 and FOXM1. From this 
catalogue, we selected a dataset of 818 breast cancer patients and we firstly evaluated HMGA1 
expression, thanks to the cBioportal tool, which is an open-access resource comprising large-scale 
genomic data about several types of cancer (Cerami et al., 2012). HMGA1 was found altered in 4% 
of TCGA dataset patients, particularly its expression level is up-regulated. Subsequently, we looked 
for FOXM1 expression level: interestingly we found that FOXM1 was enriched in HMGA1 
overexpressing patients, both at RNA and protein levels, as reported in figure 3a. We then narrowed 
our analysis on a particular subset of 174 breast cancer patients lacking the expression of the 
Oestrogen receptor, subset in which we know that HMGA1 has a major role, evaluating the 
expression of HMGA1. Among these cases, in 16% of the patients HMGA1 was found up-regulated. 
Then, we interrogated the dataset for FOXM1 expression and both RNA and protein levels were 
found enriched in HMGA1 up-regulated patients (Fig. 3b). These results suggest a tight relation 
between HMGA1 and FOXM1 expression both in breast cancer and particularly in a more specific 
subset, such as the ER- subtype, more similar to the triple negative subtype we study, suggesting that 
these two factors could work together. 
 
 
 
 
 
 
 
 
 
Figure 3: FOXM1 mRNA and protein levels are enriched in HMGA1-overexpressing breast cancer patients. a) 
Boxplots of the enrichment of HMGA1 mRNA levels with FOXM1 mRNA and protein levels in a dataset of 818 breast 
cancer patients and b) in a dataset of 174 ER-breast cancer patients. **p< 0.01. 
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2. HMGA1 and FOXM1 regulate a common gene network and similar cellular 
characteristics in TNBC 
 
2.1 HMGA1 and FOXM1 regulate a common gene network 
 
On the basis of the bioinformatic analysis and of DEG list belonging to the HMGA1/FOXM1 
network, we proceeded by validating the data we obtained using qRT-PCR, in our cellular model of 
triple negative breast cancer cell line, the MDA-MB-231. We knocked down the expression of 
HMGA1 and checked the efficacy of the silencing (Fig. 4a). Hereafter, from the DEG list, we chose 
Cyclin E2 (CCNE2), Lymphoid enhancer binding factor 1(LEF1), Snail family transcriptional 
repressor 2 (SNAI2) and Vascular endothelial growth factor (VEGFA), that are known for their role 
in malignant aspects of breast cancer, such as epithelial to mesenchymal transition, cellular migration 
and angiogenesis (Pegoraro et al., 2015; Gebeshuber et al., 2007; Chen et al., 2009; Tanaka et al., 
1993). We validated their differential expression at the two time-points chosen for the RNA-Seq 
analysis, 24 and 72 hours: as a matter of fact, as predicted by the bioinformatic analysis, we observed 
a decrease in their expression level after HMGA1 depletion (Fig. 4b). Furthermore, to generalize the 
role of HMGA1 in regulating this gene network, we confirmed these data in another cellular model 
of TNBC, the MDA-MB-157, observing, upon HMGA1 silencing, even a higher decrease in 
expression of some target genes, as in the case of SNAI2 and VEGFA (Fig. 5 a and b).  
 
Figure 4: CCNE2, LEF1, SNAI2 and VEGFA are regulated by HMGA1 in MDA-MB-231 as predicted by 
bioinformatic analysis. qRT-PCR of HMGA1 (a) and HMGA1/FOXM1 target genes (CCNE2, LEF1, SNAI2, VEGFA) 
(b) in MDA-MB-231 cells after 24- and 72 hours HMGA1 silencing (yellow and green bars respectively). GAPDH was 
used for normalization. The data are compared to control condition and are presented as the mean±SD (n = 3) *p< 0.05, 
**p < 0.01, ***p< 0.001; two-tailed Student’s t-test.  
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Figure 5: The differential expression of CCNE2, LEF1, SNAI2 and VEGFA upon HMGA1 silencing were 
confirmed in MDA-MB-157. qRT-PCR of HMGA1 (a) and HMGA1/FOXM1 target genes (CCNE2, LEF1, SNAI2, 
VEGFA) (b) in MDA-MB-157 cells after 24- and 72 hours HMGA1 silencing (yellow and green bars respectively). 
GAPDH was used for normalization.  The data are compared to control condition and are presented as the mean±SD (n 
= 3) *p< 0.05, **p < 0.01, ***p< 0.001; two-tailed Student’s t-test.  
 
Then, to confirm the functional relation between the DEG selected and FOXM1 as predicted by the 
bioinformatic analysis, we silenced FOXM1 in MDA-MB-231 cells and after 72 hours we checked 
their expression levels (Fig. 6 a and b). We observed a down-regulation of CCNE2, LEF1 and 
VEGFA, confirming FOXM1 involvement in the regulation of this gene network as was previously 
demonstrated for HMGA1.  
 
 
 
 
 
 
Figure 6: CCNE2, LEF1, SNAI2 and VEGFA are regulated by FOXM1 in MDA-MB-231 as predicted by 
bioinformatic analysis; qRT-PCR of FOXM1 (a) and HMGA1/FOXM1 target genes (CCNE2, LEF1, SNAI2, VEGFA) 
(b) in MDA-MB-231 cells after 72 hours FOXM1 silencing. GAPDH was used for normalization. The data are compared 
to control condition and are presented as the mean±SD (n = 3); **p < 0,01,***p < 0.001; two-tailed Student’s t-test.  
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Finally, with the aim of evaluating if the knocking down of both HMGA1 and FOXM1 has a higher 
impact on the expression of the DEG taken into consideration, we silenced the expression of both 
factors in MDA-MB-231 cells at the same time and, after checking the expression level of HMGA1 
and FOXM1, we evaluated the targets already mentioned (Fig. 7 a and b). Indeed, the silencing of 
both factors decreases the expression level of CCNE2, LEF1 and VEGFA more efficiently, with 
respect to the single silencing conditions. In particular, as we can observe if we compare figures 4, 6 
and 7, among the DEG evaluated, the additive effect of the co-silencing on the VEGFA expression is 
stronger with respect to the other DEG suggesting a possible synergistic action of HMGA1 and 
FOXM1 on this target.    
 
Figure 7: CCNE2, LEF1, SNAI2 and VEGFA are regulated by HMGA1 and FOXM1 in MDA-MB-231. qRT-PCR 
of HMGA1 and FOXM1 (a) and HMGA1/FOXM1 target genes (CCNE2, LEF1, SNAI2, VEGFA) (b) in MDA-MB-231 
cells after 72 hours HMGA1 and FOXM1 silencing. GAPDH was used for normalization. The data are compared to 
control condition and are presented as the mean±SD (n = 3), **p< 0.01, ***p< 0.001; two-tailed Student’s t-test.  
 
2.2 HMGA1 and FOXM1 modulate similar features of TNBC 
 
Based on the evidence that HMGA1 and FOXM1 are involved in the regulation of the same gene 
network and that we knew from previous data that HMGA1 push cancer cells to undergo an epithelial 
to mesenchymal transition (Pegoraro et al., 2013), we wondered whether FOXM1 resembles the 
action of HMGA1 in promoting malignant aspects in TNBC. With this aim, we silenced the 
expression of HMGA1 and FOXM1 in the TNBC cell lines MDA-MB-231 and -157 and evaluated 
the morphology of cells (Fig. 8 a and b). Similarly to what happens for HMGA1 silencing, after 
FOXM1 depletion, cells acquire a more flattened and polygonal structure, typical of an epithelial 
phenotype, in comparison with the control condition, where the cells show the spindle-like shape of 
mesenchymal cells. Moreover, by cosilencing the two factors, this morphological change is even 
more emphasized, suggesting, once again, a strong molecular relation between HMGA1 and FOXM1.  
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Figure 8: The silencing of HMGA1 and/or FOXM1 induces morphological changes typical of a MET in TNBC 
cells. Representative pictures of HMGA1, FOXM1 and HMGA1/FOXM1 depletion (siHMGA1, siFOXM1 and 
siHMGA1/FOXM1) in MDA-MB-231 (a) and MDA-MB-157 (b) cells, taken at X 4 magnification.    
Considering that the morphological changes observed recall a MET (mesenchymal to epithelial 
transition), we explored this scenario by evaluating a molecular marker of the MET event, such as 
Vimentin, an intermediate filament protein of the cytoskeleton, specific of the mesenchymal cells, 
which is associated with an increased cellular motility (Ivaska et al., 2007). We silenced the 
expression of HMGA1 and FOXM1 in MDA-MB-231 and we evaluated by immunofluorescence the 
cellular distribution of Vimentin. As it is possible to see in figure 9, after the silencing of HMGA1 
and FOXM1, the Vimentin network appears disrupted, forming aggregates in the cytoplasm, probably 
due to the disassembly of the protein. In addition, the expression of Vimentin seems affected, as we 
observed a lower intensity in the fluorescence signal with respect to the control condition. Moreover, 
the co-depletion of HMGA1 and FOXM1 worsened this feature, suggesting an implication of both 
proteins in the regulation of this MET marker. 
 
Figure 9: The silencing of HMGA1 and/or FOXM1 disrupts the Vimentin molecular network. Representative 
immunofluorescence images of Vimentin (green) in MDA-MB-231 cells after HMGA1, FOXM1 and HMGA1/FOXM1 
(siHMGA1, siFOXM1 and siHMGA1/FOXM1). Nuclei are stained with Hoechst (blue). Images were taken at X 40 
magnification.  
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As proved by the previous evidences, considering that HMGA1 and FOXM1 are involved in 
modulating same malignant features of TNBC, we evaluated if they synergistically promote the 
cellular migration. Thus, we knock-down the expression of HMGA1 and FOXM1 alone or in 
combination in MDA-MB-231 cells and we evaluated the migration ability of cells by wound healing 
assay. As reported in the representative images in figure 10a and in the graph in 10b, either the 
depletion of HMGA1 or FOXM1 dampened the migration capacity of the cells, but the co-silencing 
of the factors further diminishes the migratory ability of TNBC cells, in comparison to single 
silencing conditions. These results confirmed the paramount involvement of these factor in promoting 
together the motility of the cells and in turn the metastatization process in TNBC.   
 
 
 
Figure 10: HMGA1 and FOXM1 separately affect the MDA-MB-231 migration rate, but their cooperative 
action impinges on this aggressive feature at a higher extent. a) Representative images of wound closure. Images 
were taken at X 4 magnification. b) The wound areas were measured with ImageJ software and plotted on the graph. The 
data are compared to control condition and are presented as the mean±SD (n = 3), *p< 0.05, ***p< 0.001; two-tailed 
Student’s t-test. Western blot validation of HMGA1 and/or FOXM1 silencing in MDA-MB-231 cells is reported. ß-actin 
was used as a loading control.  
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3. HMGA1 regulates FOXM1 at a post-transcriptional level by retaining FOXM1 in the 
nucleus and enhancing its transcriptional activity  
 
As highlighted by the experiments done so far, HMGA1 and FOXM1 control a common gene network 
responsible for mediating several malignant features in TNBC and, interestingly, the contemporary 
presence of both factors worsened these characteristics in cancer cells, as shown by the co-silencing 
experiments. Given these premises and that FOXM1 had been indicated by the bioinformatic analysis 
as molecular partner of HMGA1, we wondered which type of relation exists between these two 
factors. HMGA1 could regulate FOXM1 gene networks working on two levels: HMGA1 could 
modulate the transcriptional activity of FOXM1 and/or it could control the expression level of 
FOXM1. Therefore, we firstly asked if HMGA1 has an influence on FOXM1 transcriptional activity: 
with this aim, we transfected the HEK293T cells with a vector containing a synthetic FOXM1-
responsive element (pGL3-5BS), represented by five repetitions of FOXM1 binding sequences 
(TAAACA) upstream of the luciferase gene (Fig. 11a), and tested its activity after HMGA1, FOXM1 
or FOXM1 plus HMGA1 over-expression. We found that HMGA1 did not have any action on this 
synthetic reporter, while, as expected, FOXM1, by binding its consensus sequence, transactivates this 
synthetic promoter of about 3-fold with respect to the control condition (Fig. 11b). More importantly, 
we found that when co-transfected with FOXM1, HMGA1 was able to cause a significant increase 
(about 35%) in the transcriptional activity of FOXM1, potentiating its action (Fig.11b). 
 
Figure 11: HMGA1 reinforces the FOXM1 transcriptional activity in an artificial reporter vector. (a) Schematic 
representation of the pGL3-5BS reporter vector with 5 binding elements of FOXM1 upstream the luciferase sequence. 
(b) HEK293T cells were transiently co-transfected with the luciferase reporter plasmid pGL3-5BS with the expression 
plasmid pEGFP-HMGA1 (green bar), pEGFP-FOXM1 (purple bar) or the combination of the two (red bar). pRL-CMV 
Renilla luciferase expression vector was included to normalize for transfection efficiencies and the measurements were 
performed with the Promega Dual-Luciferase kit. Values are reported as relative luciferase activity comparing to cells 
transfected with the reporter vector pGL3-5BS. The data are represented as the mean±SD (n > 3); *p < 0.05, **p < 0.01; 
two-tailed Student’s t-test. On the right, Western blot of GFP-HMGA1, GFP-FOXM1 or GFP-HMGA1/FOXM1, using 
an anti-GFP as primary antibody. 
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Subsequently, we asked whether HMGA1 influences the expression level of FOXM1. With this aim 
and on the basis also on the bioinformatic analysis which highlighted a slight decrease in FOXM1 
RNA level upon HMGA1 depletion (table 2b, chapter 1 of results section), we evaluated whether 
FOXM1 mRNA and protein levels were affected by HMGA1 knock-down. Thus, we silenced the 
expression of HMGA1 in MDA-MB-231 cells and evaluated the level of endogenous FOXM1 mRNA 
and protein by qRT-PCR and immunoblot analysis. As reported in figure 12 a and b, upon HMGA1 
depletion we did not detect any FOXM1 mRNA variation after 24 hours, whereas at 72 hours mRNA 
level has a little decrease and the protein is strongly reduced. Furthermore, we transfected HEK293T 
cells with FOXM1 and increasing amounts of HMGA1 and as represented in figure 12c we noticed 
that exogenous FOXM1 protein was increased in a HMGA1-dose dependent manner suggesting that 
HMGA1 stabilizes FOXM1 protein. As it is known from the literature that FOXM1 regulates its own 
mRNA and protein levels by an autoregulatory loop (Halasi and Gartel, 2009) and considering all the 
data about the expression of both endogenous and exogenous FOXM1 after HMGA1 modulation, we 
hypothesized that HMGA1 could regulate FOXM1 mainly at a post-transcriptional level, and that 
FOXM1 regulates itself at the transcriptional level on its own promoter.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: HMGA1 regulates FOXM1 expression levels mainly at post-transcriptional level. a) qRT-PCR of 
FOXM1 in MDA-MB-231 cells after 24- and 72 hours HMGA1 silencing (red and yellow bars respectively). GAPDH 
was used for normalization. The data are compared to the control condition and are presented as the mean±SD (n = 3), 
**p < 0.01; two-tailed Student’s t-test. b) FOXM1 Western blot analysis of MDA-MB-231 cells upon 72 hours HMGA1 
silencing. ß-actin was used as a loading control. c) Western blot analysis of HEK293T transfected with pEGFP-FOXM1 
and increasing amounts of pEGFP-HMGA1, using an anti-GFP as primary antibody. pRL-CMV Renilla luciferase 
expression vector was used to normalize for transfection efficiencies and the measurements were performed with the 
Promega Dual-Luciferase kit. 
 
Moreover, taking into account that one of the level of FOXM1 protein regulation is its nucleo-
cytoplasmic shuttling (Kelleher and O’Sullivan, 2016), we investigated if HMGA1 potentiates 
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FOXM1 activity by influencing also its nuclear retention. For this purpose, we evaluated, by 
immunofluorescence analysis, the cellular localization of transfected FOXM1-GFP upon HMGA1 
silencing in MDA-MB-231: indeed, in control cells FOXM1-GFP localizes in the nucleus, whereas, 
after HMGA1 depletion, FOXM1-GFP shows a more cytoplasmic localization, indicating that 
HMGA1-depletion induced the translocation of FOXM1-GFP from the nucleus to the cytoplasm (Fig. 
13). This result was even more evident when we repeated the same experiment in HEK293T cells 
that have a higher efficiency of transfection (Fig. 14).  
 
 
 
 
  
 
 
 
 
 
 
 
Figure 13: HMGA1 induces a relocalization of FOXM1 in MDA-MB-231 cells. Representative images of FOXM1-
GFP after HMGA1 silencing and pEGFP-FOXM1 transfection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: HMGA1 induces a relocalization of FOXM1 in HEK293T cells. Representative images of FOXM1-GFP 
after HMGA1 silencing and pEGFP-FOXM1 transfection.  
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Furthermore, we confirmed these results by exploring the localization of endogenous FOXM1 upon 
HMGA1 knock-down in MDA-MB-231 and -157 cell lines. We observed that the silencing of 
HMGA1 causes a more nucleo-cytoplasmic localization of FOXM1 with respect to control condition 
in which FOXM1 is more nuclear (Fig. 15 and 16). The data obtained led us to hypothesize that 
HMGA1 stabilizes FOXM1 in the nucleus and potentiates FOXM1 transcriptional activity on its 
target genes, among those FOXM1 itself.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: HMGA1 induces a cellular re-
distribution of endogenous FOXM1 in MDA-
MB-231. Representative immunofluorescence 
images of FOXM1 in after HMGA1 silencing are 
shown. Images were taken at X 60 magnification. 
 
 
Figure 16: HMGA1 induces a cellular re-
distribution of endogenous FOXM1 in MDA-
MB-157. Representative immunofluorescence 
images of FOXM1 after HMGA1 silencing are 
shown. Images were taken at X 60 magnification. 
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4. HMGA1 and FOXM1 synergistically mediate the transcription of the VEGFA 
 
Our data indicate that with high level of HMGA1, FOXM1 shows a more nuclear distribution; 
moreover, HMGA1 increases FOXM1 transcriptional activity and guides the control of a common 
gene network in TNBC. In literature, it is reported the involvement of FOXM1 in the angiogenic 
process, particularly in regulating VEGFA transcription by directly binding its promoter (Zhang et 
al., 2008; Karadedou et al., 2012), while very little is known about the role of HMGA1 in this process. 
Although some reports demonstrated that HMGA1 transcriptionally regulates VEFGA (Messineo et 
al., 2016). 
By analysing the TCGA dataset, we evaluated the expression of VEGFA mRNA in HMGA1 over-
expressing breast cancer patients. As shown in figure 17, we found a strong enrichment of VEGFA 
in this subset of patients, supporting the hypothesis of a role of HMGA1 in the angiogenic context 
and an involvement in VEGFA expression. In addition, as shown before, we demonstrated that 
HMGA1 and FOXM1 have a slight effect on VEGFA expression, whereas the co-silencing of the two 
factors induced a stronger reduction in VEGFA expression (Fig. 18 a and b).  
 
 
 
 
 
 
 
Figure 17: VEGFA mRNA level is enriched in HMGA1-overexpressing patients.  Boxplots of the enrichment of 
HMGA1 mRNA levels with VEGFA mRNA in a dataset of 818 HMGA1-overexpressing breast cancer patients. **p< 
0.01. 
 
 
 
 
 
 
 
Figure 18: HMGA1 and FOXM1 regulate VEGFA expression. a) qRT-PCR of VEGFA in MDA-MB-231 cells after 
72 hours HMGA1, FOXM1 and HMGA1/FOXM1 silencing. GAPDH was used for normalization. The data are compared 
to control and are presented as the mean±SD (n = 3); **P < 0.01, ***P<0.001; two-tailed Student’s t-test. b) VEGFA 
Western blot analysis of MDA-MB-231 cells upon 72 hours HMGA1, FOXM1 and HMGA1/FOXM1 silencing. ß-actin 
was used as a loading control.  
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On the basis of these evidences and considering the key role of the angiogenic process in promoting 
the progression of breast cancer, we investigated if HMGA1 controls VEGFA transcription and 
whether it has an impact on the transcriptional activity of FOXM1 on the VEGFA promoter.  
To study the action of HMGA1 and FOXM1 on the transcriptional regulation of VEGFA we used a 
luciferase reporter vector containing a region of the VEGFA promoter spanning from -1000 to -1 bp 
from the transcriptional start site (TSS). Firstly, we transfected the HEK293T cells with the luciferase 
promoter and increasing amounts of FOXM1 and HMGA1 expressing vectors. As reported in figure 
19 a and b, we observed that not only FOXM1 but also HMGA1 increases VEGFA-luciferase activity. 
Thus, we co-transfected FOXM1 and increasing quantities of HMGA1, in order to see if HMGA1 
has an effect on FOXM1 activity. Indeed, HMGA1 enhances FOXM1 transcriptional activity on 
VEGFA promoter, in a dose dependent manner (Fig. 19 c).  
 
 
Figure 19: HMGA1 enhances FOXM1 
transcriptional activity in a dose-
dependent manner on a VEGFA 
promoter. HEK293T cells were 
transiently co-transfected with the 
luciferase reporter plasmid pGL4.10-
VEGFprom (-1000-1) with the expression 
plasmid pEGFP-FOXM1 at increasing 
concentrations (a), pEGFP-HMGA1 at 
increasing concentrations (b) and pEGFP-
FOXM1 and increasing quantities of 
pEGFP-HMGA1 (c). pRL-CMV Renilla 
luciferase expression vector was included 
to normalize for transfection efficiencies. 
Values are reported as relative luciferase 
activity comparing to cells transfected with 
the reporter vector pGL4.10-VEGFprom (-
1000-1). The data are compared to control 
condition and are represented as the 
mean±SD (n > 3). **P < 0.01, 
***P<0.001; two-tailed Student’s t-test. 
On the right, are reported the 
correspondent Western blot validation. 
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In addition, to further explore the tight dependence of FOXM1 transcriptional activity on HMGA1, 
we silenced the expression of HMGA1 and transfected FOXM1 in HEK293T cells.  
We observed (Fig. 20) that the transfection of FOXM1 strongly increases the activity of the luciferase, 
while the silencing of endogenous HMGA1 does not have any significant effect on the transactivation 
of this promoter. When we overexpressed FOXM1 and at the same time we silence the expression of 
HMGA1 we observed a significant reduction of FOXM1 ability in inducing the activity of the reporter 
gene. These results confirmed that HMGA1 boosts FOXM1 activity on VEGFA promoter.  
 
 
Figure 20: FOXM1 transcriptional action on VEGFA promoter is dependent on HMGA1. HEK293T cells silenced 
for HMGA1 by siRNA and transiently cotransfected with the luciferase reporter plasmid pGL4.10-VEGFprom (-1000-1) 
with the expression plasmid pEGFP-FOXM1. pRL-CMV Renilla luciferase expression vector was included to normalize 
for transfection efficiencies. Values are reported as relative luciferase activity comparing to cells transfected with the 
reporter vector pGL4.10-VEGFprom (-1000-1). The data are represented as the mean±SD (n > 3), *p< 0.05; two-tailed 
Student’s t-test. On the right, the correspondent western blot validation. ß-actin was used as a loading control for 
endogenous HMGA1.  
 
5. Identification of FOXM1 putative binding sites relevant for HMGA1 activity on the 
VEGFA promoter 
 
Subsequently, we asked where HMGA1 and FOXM1 exert their transcriptional action along VEGFA 
promoter and for this reason we analysed the -1000 to -1 bp sequence of VEGFA promoter used by 
searching sequence elements important for the two factors. Specifically, for HMGA1 we looked for 
AT-rich regions searching for at least three consecutive A or T (Watanabe et al., 2013), and for 
FOXM1 we looked for its consensus sequence, which is the common binding element of Forkhead 
family proteins: in particular, we considered the sequence RYAAAYA (R can be A or G and Y can 
be substituted with C or T)  (Littler et al., 2010). The schematic representation of the analysis 
performed is illustrated in figure 21. We found several AT-rich sequences (indicated with a red arrow 
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in the figure) particularly present in the region from – 979 to 907 bp, from -641 to -521 bp, from -355 
to -322 bp, from -169 to -75 bp, where the AT stretches are particularly long, and from -17 to -13 bp 
from the TSS of the VEGFA promoter. In addition, we found 9 putative FOXM1 binding sites 
(represented as yellow boxes in the figure) from -993 to -922 bp, from -643 to - 638 bp, from -326 to 
-322 bp, from -124 to -104 bp, where it is located the FOXM1 preferential binding sequence 
TAAACA, and from -17 to -13 bp from the TSS of the VEGFA promoter.  
 
 
 
Figure 21: VEGFA promoter vector contains several putative HMGA1 and FOXM1 binding regions. Schematic 
representation of the bioinformatic analysis of the 1000 bp of VEGFA promoter used in reporter experiments. FOXM1 
binding sites are represented with yellow boxes, whereas the AT-enriched sequences bound by HMGA1 are figured as 
red arrows.  
 
On the basis of this analysis, we decided to explore whether the cooperative action of HMGA1 and 
FOXM1 occurs in the region spanning from -1000 to -500 or from -500 to -1 (Fig. 22a). We thus 
transfected the HEK293T cells with the reporter vectors pVEGFprom (-1000-1), pVEGFprom (-
1000-500) and pVEGFprom (-500-1) and with the same amount of plasmids for over-expressing 
HMGA1 and FOXM1. The activation of the luciferase by HMGA1 and FOXM1 in the deletion 
mutants was compared to the full length VEGFA promoter (-1000 to -1 bp), in order to compare the 
action of the two factors in these three promoter constructs. As shown in figure 22b, the synergic 
action of HMGA1 and FOXM1 drops in the mutant promoter -1000 to -500 bp while it remains 
constant in the -500 to -1 bp VEGFA promoter, with respect to the full-length promoter condition. 
From this experiment, we inferred that the region of the VEGFA promoter where the action and the 
binding of HMGA1 and FOXM1 are mainly localized goes from -500 to -1 bp.   
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Figure 22: The cooperative action of HMGA1 and FOXM1 resides mainly in (-500-1 bp) VEGFA promoter 
region. a) Schematic representation of deletion reporter vectors transfected; b) HEK293T cells were transiently 
cotransfected with the luciferase reporter plasmid pVEGFprom (-1000-1), the deletion mutants pVEGFprom (-1000-500) 
or pVEGFprom (-500-1) with the expression plasmids pEGFP-HMGA1 and pEGFP-FOXM1. pRL-CMV Renilla 
luciferase expression vector was included to normalize for transfection efficiencies. Values are reported as relative 
luciferase activity comparing to cells transfected with the reporter vector pVEGFprom (-1000-1). The data are represented 
as the mean±SD (n > 3). NS: not significant; two-tailed Student’s t-test. An example of western blot validations is reported. 
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Furthermore, in order to narrow down the regulatory region involved in the transcriptional control by 
HMGA1 in cooperation with FOXM1 we introduced progressive deletion of the -500-1 bp VEGFA 
promoter (Fig. 23a), on the basis of the presence of AT-rich regions and the FOXM1 putative binding 
sites and we generated the following constructs: 
 
➢ pVEGFprom (-338 to -1) bp from the TSS comprising all the AT rich sequences and the FOXM1 
binding elements and excluding the region between -500 -338 bp, where no putative binding sites 
for both factors were found; 
➢ pVEGFprom (-172 to -1) bp from the TSS excluding one putative binding site for HMGA1 and 
FOXM1, but comprising all the long AT stretches and the preferential FOXM1 putative binding 
site described above. 
➢ pVEGFprom (-104 to -1) bp from the TSS which excluded the specific putative binding sites for 
FOXM1 and all the long AT sequences of HMGA1, including only a region containing one 
putative binding site for FOXM1 (-17 to -13 bp). 
 
Thus, we transfected these VEGFA deletion mutant reporter vectors together with expression vectors 
for HMGA1 and FOXM1 and evaluated the luciferase activity of these constructs with respect to the 
pVEGF prom (-500 to -1) bp reporter, (Fig. 23b). Specifically, we observed that FOXM1 maintains 
its transcriptional activity in all the reporters, except in the construct pVEGF prom (-104 to -1) bp 
promoter, where there is a decrease probably due to the loss of its preferential binding site which is 
located at -124 -118 bp of VEGFA promoter (Fig. 23b see purple bars). Overexpression of HMGA1 
does not increase the activity of all three mutant reporters, in comparison with the pVEGF prom (-
500 to -1) bp promoter (Fig. 23b see green bars), revealing the importance of the region spanning 
from -500 to -338 bp for its activity, even though from the analysis we made this region does not 
contain any AT stretch. Finally, we found that even if HMGA1 loses its ability to transcriptionally 
regulate the deletion mutants, it maintains its capacity to potentiate the activity of FOXM1 both on 
pVEGF prom (-338-1) bp and pVEGF prom (-172-1) bp luciferase vectors, whereas, on the pVEGF 
prom (-104 to -1) bp promoter, it fails in increasing FOXM1 activity (Fig. 23b see red bars).    
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Figure 23: HMGA1 enhances the luciferase activity on VEGFA promoter in two independent fashions. a) 
Schematic representation of deletion reporter vectors transfected. b) HEK293T cells were transiently co-transfected with 
the luciferase reporter plasmid pGL4.10-VEGFprom (-500-1), the deletion mutants pGL4.10-VEGFprom (-338-1), 
pGL4.10-VEGFprom (-172-1) or pGL4.10-VEGFprom (-104-1) with the expression plasmid pEGFP-HMGA1(green 
bar), pEGFP-FOXM1 (purple bar) and pEGFP-HMGA1/pEGFP-FOXM1 (red bar). pRL-CMV Renilla luciferase 
expression vector was included to normalize for transfection efficiencies. Values are reported as relative luciferase activity 
comparing to cells transfected with the reporter vectors used. The data are represented as the mean±SD (n > 3). *p<0.05, 
**p<0.01, ***p<0.001, NS: not significant; two-tailed Student’s t-test. An example of western blot validations is reported. 
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These results led us to conclude that HMGA1 acts on VEFGA promoter through two independent 
ways:  
- a FOXM1-independent mechanism that resides in the region from -500 to -338 bp of the promoter;  
- a FOXM1-dependent mechanism since it is able to potentiate FOXM1 transcriptional activity, 
mainly in the region from -338 to -104 bp of VEGF promoter, where we detect most of the 
cooperative action between HMGA1 and FOXM1. 
 
6. HMGA1 acts on VEGFA promoter through two transcriptional factors: Sp1 and FOXM1 
 
Given the data obtained and since the analysis we carried out did not reveal any AT stretch in the 
region from -500 to -338 bp of VEGF promoter, we hypothesized that the FOXM1-independent action 
of HMGA1 on the VEGFA promoter is mediated through other factors, possible molecular partners 
of HMGA1. We thus searched in the literature other known important factors involved in the 
transcription of VEGFA in the region -500 to -338 bp and we found that the binding of a well-known 
transcription factor, Sp1, occurs in the region from -385 to -352 bp of VEGFA promoter. Specifically, 
in this region three Sp1 binding sites (Sp1 consensus sequence: 5’-GGGCGG-3’) are described and 
it has been demonstrated that when the first and the second binding sites are mutated, the activity of 
Sp1 in VEGFA promoter decreases significantly (Pore et al., 2004). Intriguingly, it has been reported 
that HMGA1 cooperates with Sp1 in regulating gene expression. For example, HMGA1 physically 
interacts with Sp1 and supports its binding to the Insulin receptor promoter (Foti et al., 2003). 
Therefore, we decided to further explore whether HMGA1 cooperates with Sp1 on the VEGFA 
promoter, by introducing a further deletion in -500 -388 bp and mutating the two Sp1 binding sites 
described by Pore N. and colleagues (Fig. 24a), in this new deletion mutant pVEGFprom(-388-1). 
We transfected the HEK293T cells with the pVEGFprom(-500-1), pVEGFpromWT(-388-1) and 
pVEGFpromMUT(-388-1) reporters and evaluated by luciferase assay the activity of HMGA1 and 
FOXM1 alone or in combination on the activation of these promoters. As shown in figure 24b, the 
transcriptional activity of HMGA1 persists in the pVEGFpromWT(-388-1) with respect to the 
pVEGFprom(-500-1), highlighting that the action of HMGA1 does not occur in the region from -500 
to -388 bp of the promoter (Fig. 24b, see green bars). Very interestingly, when we mutate Sp1 binding 
elements, HMGA1 is not able to transactivate the pVEGFpromMUT(-388 to -1), drawing the 
attention on the dependence of HMGA1 upon Sp1 factor on this promoter region (Fig. 24b, see green 
bars). In addition, when we transfected FOXM1, in all the reporters used in this experimental setting 
the activity is comparable to the pVEGFprom(-500-1) (Fig. 24b, see purple bars), consistently with 
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the analysis presented above. Finally, if we co-transfected HMGA1 and FOXM1, the synergic activity 
of the factors is not affected by the mutation of Sp1 elements (Fig. 24b, see red bars). This evidence 
confirmed our previous hypothesis speculating two independent mechanisms of action of HMGA1 
on VEGFA promoter: the first one that we demonstrated goes by SP1 binding to the region -385 to   
-352 bp of the VEGFA promoter and the second one which involves the cooperation with FOXM1.  
 
 
 
 
 
 
 
 
 
 
 
Figure 24: HMGA1 transcriptional activity on VEGFA promoter is dependent upon SP1 and FOXM1 in 
different promoter regions. a) Schematic representation of deletion reporter vectors transfected b) HEK293T cells were 
transiently cotransfected with the luciferase reporter plasmid pGL4.10-VEGFprom (-500-1), the deletion mutants 
pGL4.10-VEGFprom (-388-1) wild-type or mutated in SP1-binding sites with the expression plasmisd pEGFP-
HMGA1(green bar), pEGFP-FOXM1 (purple bar) or pEGFP-HMGA1/ pEGFP-FOXM1 (red bar). pRL-CMV Renilla 
luciferase expression vector was included to normalize for transfection efficiencies. Values are reported as relative 
luciferase activity comparing to cells transfected with the reporter vectors used. The data are normalized to control 
condition and represented as the mean±SD (n > 3). **p<0.01, ***p<0.001, NS: not significant; two-tailed Student’s t-
test. An example of western blot validations is reported. 
 
 
Subsequently, in order to deeply investigate the FOXM1-dependent activity of HMGA1, we carried 
out a reporter assay in HEK293T cells with the pVEGFpromWT(-388 to -1) or pVEGFpromMUT(-
388 to -1) and the pVEGFprom(-338 to -1) and we evaluated the luciferase activity upon FOXM1 
knock-down and HMGA1 overexpression. As reported in figure 25, the silencing of endogenous 
FOXM1 diminishes the luciferase activity in all the reporters used, regardless of the presence of Sp1 
binding elements, underlying once again the importance of this factor on the VEGFA transcription. 
Moreover, the HMGA1 overexpression increases the pVEGFpromWT(-388 to -1) promoter activity, 
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as expected, while this increment is lower in pVEGFpromMUT(-388 to -1) or in the pVEGFprom(-
338 to -1), confirming the dependence of HMGA1 upon Sp1. When we silenced the expression of 
FOXM1, HMGA1 over-expression is not able to induce the same level of luciferase activation of all 
the three reporters taken into consideration. Moreover, by comparing the silencing conditions (yellow 
bars), the overexpression of HMGA1 increases the VEGFA transcription to some extent only in the 
pVEGFpromWT(-388 to -1), while the mutation or the deletion of Sp1 binding elements diminishes 
HMGA1 ability to increase luciferase, confirming the existence of two different ways this factor 
works through, both pivotal for driving VEGFA transcription by HMGA1 (Fig. 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: The deletion of SP1 binding sites is sufficient to decrease the HMGA1 transcriptional activity on 
VEGFA promoter but is not necessary for its FOXM1-dependent action.  HEK293T cells were silenced for 
FOXM1 expression and transiently co-transfected with the luciferase reporter plasmid pGL4.10-VEGFprom (wild type -
388-1), pGL4.10-VEGFprom (SP1 mutated -388-1) or pGL4.10-VEGFprom (-338-1) with the expression plasmids 
pEGFP-HMGA1. pRL-CMV Renilla luciferase expression vector was included to normalize for transfection efficiencies. 
Values are reported as relative luciferase activity comparing to cells transfected with the reporter vectors used. The data 
are normalized to control condition and are represented as the mean±SD (n > 3). **p<0.01, ***p<0.001; two-tailed 
Student’s t-test. An example of western blot validations is reported. ß-actin was used as a loading control for endogenous 
FOXM1. 
 
On the other hand, the ability of FOXM1 to induce VEGFA-luciferase reporter is dependent only on 
the presence of HMGA1 and not on that of Sp1. In fact, the overexpression of FOXM1 increases the 
VEGFA promoter transactivation regardless the presence of Sp1 binding elements as described before 
(Fig. 26). In addition, the presence of endogenous HMGA1 is crucial for FOXM1 activity, because 
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when we depleted the cells of this factor, FOXM1 decreases its transcriptional action on VEGFA 
promoter at the same extent both in the wild-type and in the Sp1-mutated vector. 
 
 
Figure 26: FOXM1 action on VEGFA promoter does not need SP1 factor but is strictly dependent upon HMGA1 
action. HEK293T cells were silenced for HMGA1 expression and transiently co-transfected with the luciferase reporter 
plasmid pGL4.10-VEGFprom (wild type -388-1) or pGL4.10-VEGFprom (SP1 mutated -388-1) with the expression 
plasmid pEGFP-FOXM1. pRL-CMV Renilla luciferase expression vector was included to normalize for transfection 
efficiencies. Values are reported as relative luciferase activity comparing to cells transfected with the reporter vectors 
used. The data are represented as the mean±SD (n > 3). ***p<0.001; two-tailed Student’s t-test. An example of western 
blot validation is reported. ß-actin was used as a loading control for endogenous HMGA1.   
 
All these experiments underline the importance of HMGA1 and FOXM1 in regulating VEGFA 
transcription. Specifically, they pointed out that HMGA1 acts in at least two different ways, one 
dependent on Sp1 transcription factor and the other one on FOXM1 factor. Moreover, the results 
underline the tight cooperation between HMGA1 and FOXM1 in enhancing the transcription of the 
VEGFA factor, pivotal for the angiogenic process. 
 
 
 
 
 
 
 
 
 
68 
 
 7. HMGA1 and FOXM1 induce TNBC cells to influence pivotal angiogenic processes of 
endothelial cells 
 
We showed that HMGA1 and FOXM1 regulate the transcription of VEGFA, one of the most crucial 
factor in inducing the angiogenic process which is an important cancer hallmark. For this reason, in 
collaboration with the laboratory of Professor Roberta Bulla at the Department of Life Sciences of 
the University of Trieste, we decided to explore if HMGA1 and FOXM1 drive TNBC cells to 
influence the surrounding endothelial cells, enhancing their angiogenic properties and leading to the 
formation of new vessels important for tumor survival and spreading.  
We then performed different in vitro experiments to test the ability of MDA-MB-231 supernatant in 
modulating angiogenesis. To this end, we proceeded by analysing if breast cancer cells influence 
some pivotal properties of endothelial cells, such as cellular proliferation and migration. Thus, we 
silenced the expression of HMGA1 and FOXM1 alone or in combination in MDA-MB-231 cells and 
treated the HUVEC endothelial cells with the supernatant collected by the cancer cells. In order to 
assess the proliferation rate, we measured the Ki67 marker, factor present in the active phases of the 
cell cycle (Scholzen and Gerdes, 2000). We observed that the endothelial cells grow to a lower rate 
if treated with the supernatants of cells silenced for HMGA1 and FOXM1 expression; nevertheless, 
the cosilencing of the two factors does not potentiate the effect of the single silencing conditions (Fig. 
27a). In addition, we investigated the migration rate of endothelial cells, pivotal aspect for the 
angiogenic process. We treated the HUVEC cells with the supernatants of MDA-MB-231 depleted 
for HMGA1 and FOXM1; the single silencing conditions decrease the ability of the endothelial cells 
to migrate, while the co-silencing of HMGA1 and FOXM1 does not further boost this effect (Fig. 
27b). From these experiments, we concluded that HMGA1 and FOXM1 individually control 
proliferation and migration rates of endothelial cells, considering that the cosilencing does not 
potentiates the action of the breast cancer cells on the aspects analysed.  
 
 
 
 
 
 
 
 
69 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: HMGA1 and FOXM1 induce the TNBC cells to enhance in turn the proliferation and migration 
abilities of endothelial cells. HUVEC endothelial cells were treated with MDA-MB-231 supernatants, who had been 
previously silenced for HMGA1, FOXM1 or cosilenced for HMGA1 and FOXM1. Serum-free medium and normal horse 
serum were used as negative and positive controls respectively. a) The cells proliferation was investigated by the positivity 
to the Ki67 marker and expressed in terms of fluorescence units. The comparison has been done with respect to the 
siCTRL condition. The data are represented as the mean±SD (n > 3). b) The migration of endothelial cells was assessed 
by Transwell assay, adding the supernatants of MDA-MB-231 in the lower chambers of the multiwell. The number of 
cells migrated were counted and the results are expressed as % of migration, respect to the siCTRL condition. The data 
are represented as the mean±SD (n > 3). *p<0.05, **p<0.01, ***p<0.001; two-tailed Student’s t-test. Western blot 
validations of HMGA1/FOXM1 silencing in MDA-MB-231 cells is reported. ß-actin was used as a loading control. 
 
Finally, we evaluated the ability of endothelial cells to form capillary-like structure, a crucial aspect 
of the angiogenesis, in response to breast cancer supernatants induction. To this aim we plated 
HUVEC cells on a Matrigel support and incubated them with the supernatant of MDA-MB-231 cells 
depleted for HMGA1, FOXM1, or a combination of both. As represented in figure 28a, the 
supernatants of control breast cancer cells induce the formation of capillary-like structures of 
endothelial cells at a level comparable to the one obtained by HUVEC cells stimulated by VEGFA, 
as a positive control. This result indicates the pro-angiogenic potential of the TNBC cells we used. 
Furthermore, if we give the supernatant of MDA-MB-231 cells silenced for HMGA1 and FOXM1 to 
endothelial cells, they lose their ability to organize themselves in a vessels network. Very 
interestingly, when we knocked down the expression of HMGA1 and FOXM1 together, the ability 
of HUVEC cells to form capillary structures is severely compromised. The number of vessels formed 
by endothelial cells were then counted and plotted in the graph in figure 28b. The induction of the 
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TNBC cells in promoting vessels formation is comparable to the positive control condition in which 
VEGFA was added, in terms of number of structures formed. The depletion of HMGA1 and FOXM1 
in breast cancer cells decreased by 50% the tube formation capacity of HUVEC cells while the co-
silencing of these factors further decreases the formation of capillaries in a significant manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: HMGA1 and FOXM1 in TNBC cells strongly induce the endothelial cells to organize themselves in 
a vessel-like network. a) Representative immunofluorescence images of the vessels formed. Capillary-like structures 
were allowed to form from endothelial cells exposed to VEGFA as a positive control or to supernatants of MDA-MB-
231 cells silenced for HMGA1, FOXM1 or HMGA1/FOXM1 on Matrigel. b) The number of vessels formed by HUVEC 
cells were counted and plotted on the graph. The data are expressed respect to siCTRL condition and are represented as 
the mean±SD (n = 4). **P<0.01, ***P<0.001; two-tailed Student’s t-test is calculated respect to siCTRL. 
This experiment, which mimics better the angiogenic process with respect to the measure of 
proliferation and migration rates, confirmed the positive stimulus of the TNBC cells in enhancing the 
angiogenesis carried out by the surrounding endothelial cells. Moreover, it confirms the key role of 
HMGA1 and FOXM1 in breast cancer cells in promoting several angiogenic aspects of endothelial 
cells, by acting in a synergistical manner. 
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8. HMGA1 and FOXM1 regulate a specific angiogenic-transcriptional programme 
 
In support of these experiments, in collaboration with the Bioinformatic unit of LNCIB in Trieste, we 
performed a bioinformatic analysis aimed to unravel other possible factors, regulated by HMGA1 
and FOXM1, with a role in the angiogenic process. We thus performed a gene ontology analysis on 
the differentially expressed genes upon HMGA1 silencing and found more than 100 angiogenic 
factors whose expression is modulated by the depletion of HMGA1 in MDA-MB-231 TNBC cells 
(table 3a). Furthermore, a considerable amount of genes related to properties associated with 
angiogenesis were found significantly affected by HMGA1 knock-down (table 3a). The number of 
genes per function and the high significance of the data suggest an important involvement of HMGA1 
in regulating these angiogenic-related processes. In addition, we crossed the DEG found with the 
FOXM1 network obtained by Ingenuity pathway analysis software, and we discovered several 
angiogenic factors, other than VEGFA, regulated by the two factors, both in angiogenic and in other 
angiogenic-related processes, such as the morphology of the cardiovascular system and the 
vasculogenesis (table 3b). Very interestingly, we found factors, such as CCNE2 and LEF1, whose 
differential regulation upon HMGA1 and FOXM1 expression had already been validated (see Fig. 4-
7 section Results). Indeed, the silencing of HMGA1 and FOXM1 decreased the level of expression 
of these targets, whereas the co-depletion of HMGA1 and FOXM1 increased the effect of single 
factors. These data strongly support the involvement of HMGA1 and FOXM1 in the regulation of the 
angiogenic process, not only by modulating VEGFA, but also controlling other factors, and in other 
cellular processes related to it.   
 
 
 
 
 
 
Table 3: Several factors belonging to angiogenic-related functions are induced by HMGA1 and FOXM1’s 
cooperative action. a) A Gene ontology analysis was carried out on DEG upon HMGA1 silencing in MDA-MB-231 
cells to cluster these genes in functions related to angiogenesis. The functions are ranked by p-value and the number of 
genes found to be regulated by HMGA1/function was annotated. b) The DEG of angiogenesis-related functions were 
crossed with the HMGA1/FOXM1 network and the factors involved in angiogenesis and its related functions were listed.  
72 
 
9. TNBC cells promote the angiogenic process in an in vivo model of Zebrafish  
 
Considering the role of TNBC cells in promoting angiogenesis under the guidance of HMGA1 and 
FOXM1, we investigated whether cancer cells are able to influence the formation of new blood 
vessels also in an in vivo animal model. In order to evaluate the potential action of TNBC cells in 
vivo, we took advantage of Danio rerio (Zebrafish) embryos, which is a well-established animal 
model to study angiogenesis. As a matter of fact, Zebrafish embryos develop a circulatory system 
within one day after fertilization and it is possible to easily visualize the vessels due to the optical 
transparency of embryos. Moreover, the larvae manipulation and injection are simple, and no 
xenograft rejection occurs since the immune system is not mature enough at this stage (Tobia et al., 
2011). Thus, in collaboration with the laboratory of Cristina Zennaro at the Department of Medical, 
Surgery and Health Sciences of the University of Trieste, we co-silenced the expression of HMGA1 
and FOXM1 via siRNA in MDA-MB-231 cells and injected the cells in the yolk sack of Zebrafish 
embryos, two days after the fertilization. Firstly, we monitored the dimension of the tumor mass, 
which had colonized the site of injection, at one and three days after the injection in embryos. As 
reported in figure 29a, the dimension of the tumoral mass of MDA-MB-231 knocked-down for 
HMGA1 and FOXM1 decreases in comparison with the control cells within three days after injection. 
Moreover, we observed that the tumor mass in the cosilencing condition is less compact with respect 
to the control condition at three days post injection (representative images in figure 29 b and c). We 
assessed the proliferation index by measuring the Ki67 marker and noticed that the TNBC cells 
depleted of HMGA1 and FOXM1 proliferate less compared to control cells, specifically at day one 
post injection. This result was then reverted at three days post injection, probably due to the loss of 
the silencing effect in TNBC cells (Fig. 29d). These observations brought to light the evidence that 
the co-silencing of HMGA1 and FOXM1 has a strong impact on the growth of the primary tumor, 
underlying the importance of these factors in promoting cancer. 
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Figure 29: HMGA1 and FOXM1 increase the tumor mass in vivo.  Evaluation of tumor mass growth in Zebrafish 
larvae after 1 and 3 days post injection of MDA-MB-231 cosilenced for HMGA1 and FOXM1 (1 dpi and 3 dpi). a) 
Western blot validations of HMGA1/FOXM1 silencing is reported. ß-actin was used as a loading control. Tumor mass 
evaluation was expressed as percentage of siHMGA1/FOXM1 with respect to siCTRL condition, normalized to 1dpi. The 
data are represented as the mean±SD (n = 10); b) Representative live images of tumor mass in larvae at 1 dpi and 3 dpi. 
Overlapping immunofluorescence images of the tumor mass are reported. c) Control and siHMGA1/FOXM1 MDA-MB-
231 tumor mass evaluation in immunofluorescence at 1 and 3 days post injection. d) qRT-PCR analysis of hKi67 at 1 and 
3 dpi. Data were normalized to the human GAPDH mRNA amount. The data are represented as the mean±SD (n = 10). 
 
From these preliminary experiments, we decided to perform the evaluation of the angiogenic process 
at day one after TNBC cells injection. Therefore, the co-silenced cells were injected in Zebrafish 
embryos and the proliferation rate of the tumor mass was assessed by Ki67 measurement, (Fig. 30a). 
Subsequently, we evaluated the vessels of the sub-intestinal venous plexus (SIV), since it is an easily 
observable vessels network at only 2 days post fertilization (Goi and Childs, 2016), (Fig. 30b). 
Specifically, we investigated whether the co-depletion of HMGA1 and FOXM1 affects the normal 
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development of this circulatory system; we noticed that HMGA1 and FOXM1 silencing reverts the 
alteration observed in control cells, almost to the normal condition (Fig. 30b). Then, we counted the 
number of larvae whose SIV was branched and plotted the results on a graph (Fig. 30c): the knock-
down of the HMGA1 and FOXM1 decreases the number of embryos altered in their sub-intestinal 
vessels with respect to the control condition, where more than half of the larvae taken into 
consideration was altered.  
 
Figure 30: The synergic action of HMGA1 and FOXM1 of MDA-MB-231 cells induce the angiogenic process 
in vivo.  a) Validation of proliferation of control and HMGA1/FOXM1 TNBC cells by qRT-PCR analysis of hKi67 at 1 
dpi. Data were normalized to the human GAPDH mRNA amount. The data are represented as the mean±SD (n = 10). 
***p<0.001. b) Schematic representation of the sub-intestinal venous plexus (SIVP) evaluated for the assessment of the 
Zebrafish angiogenic process. Representative images of vessels of the SIVP. The medium was used as a negative control. 
c) The larvae with a branched SIVP (red) or unaltered SIVP were counted and plotted on the graph, expressed in 
percentage (n = 22). 
 
Furthermore, in order to better investigate the level of alteration of the vessels network, several 
specific parameters of the SIV were considered. The length, area and diameter of the SIV were 
measured and it was assessed that the knock down of HMGA1 and FOXM1 decreases the alteration 
on these parameters to the level of an unstimulated situation, while control cells significantly modify 
the structure of the SIV plexus (Fig. 31 a, b and c).  
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Figure 31:  TNBC cells under the driving forces of HMGA1 and FOXM1 affect the length, area and diameter 
of the sub-intestinal venous plexus of Zebrafish larvae. The SIVP vessels parameters taken into account were 
measured in Zebrafish larvae at 1 dpi of MDA-MB-231 cells silenced for HMGA1 and FOXM1 (a, b and c respectively). 
The data are normalized to control and are represented as the mean±SD (n = 22). *p<0.05, **p<0.01, ***p<0.001. 
 
Finally, the level of expression of several Zebrafish angiogenic markers were evaluated in qRT-PCR. 
Specifically, the co-silencing of HMGA1 and FOXM1 reduces significantly the level of expression 
of Zebrafish Vegfa2 and its receptors Ftl-1 and Flk-1, confirming the action of MDA-MB-231 cells 
on Zebrafish endothelial cells (Fig. 32). 
 
 
Figure 32: HMGA1 and FOXM1 in TNBC cells induce the expression of Zebrafish angiogenic molecular 
targets. qRT-PCR analysis of zebrafish VEGFA, FLT1 and FLK1 at 1dpi. Data were normalized to the Zebrafish actin 
mRNA amount. The data are compared to the respective controls and are represented as the mean±SD (n = 22). 
***p<0.001. 
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The results obtained in this animal model sustained the observations made in the in vitro experiments 
about the vital importance of HMGA1 and FOXM1 in leading the breast cancer cells to modulate the 
angiogenic potential of Zebrafish endothelial cells.  
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Discussion and 
Conclusions 
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HMGA1 has been widely proved to have a causal role in breast cancer, both at early stages, bringing 
the mammary epithelial cells to acquire a malignant phenotype (Ram et al., 1993, Reeves et al., 2001), 
and during breast cancer progression, by promoting the cellular migration and invasion capacities, 
thus leading to the metastatization event (Pegoraro et al., 2013; Shah et al., 2013). In addition, 
HMGA1 expression is particularly enriched in the basal-like breast cancer subtype in comparison to 
other subtypes, demonstrating its correlation with an advanced tumor stage (Pegoraro et al., 2013). 
All these evidences demonstrated how HMGA1 is a crucial factor for breast cancer and how 
deepening the knowledge about the features it controls will be paramount for the discovery of new- 
more targeted and efficacious therapies. Given these premises, the aim of this work was to find new 
molecular partners HMGA1 could synergistically work with in regulating common gene networks, 
implicated in breast cancer hallmarks. HMGA1 is an architectural transcription factor binding general 
AT-enriched sequences on the DNA rather than specific regulatory elements; moreover, by 
interacting with a plethora of transcription factors, guides their transcriptional action on a high 
number of targets involved in many cellular processes, such as cell growth, proliferation, 
differentiation and cell death (Cleynen and Van de Ven, 2008), aspect which characterizes HMGA1 
as a molecular instigator in normal and tumoral cells. Thus, by bioinformatic analysis on differentially 
expressed genes upon HMGA1 silencing in a model of TNBC cells, we identified several possible 
molecular partners of HMGA1 in regulating common gene networks in breast cancer. Among the 
factors obtained, we found RB1, E2F and STAT3, whose connection with HMGA family members 
has been described. Specifically, HMGA2 enhances E2F transcriptional activity by directly binding 
RB1, inducing the development of pituitary adenomas (Fedele et al., 2006a); furthermore, HMGA1 
regulates STAT3 by directly binding its promoter, causing haematological malignancies (Bowman et 
al., 2000). Our data suggest that HMGA1 could work with these factors also in breast cancer 
progression, indicating common crucial HMGA1-oncogenic pathways in different cancer types. 
Basing on the fact that the role of HMGA factors has been already explored in association with these 
factors, we focused on FOXM1, a transcription factor primarily involved in cell cycle regulation 
(Wierstra and Alves, 2007), with a well-known role in breast cancer onset and progression (Saba et 
al., 2016). Considering all these aspects and that very little is known about the relation between 
HMGA1 and FOXM1, we decided to explore the molecular connection occurring between HMGA1 
and FOXM1, new putative molecular partner of HMGA1. We thus explored the downstream gene 
network in common between HMGA1 and FOXM1 and we focused in particular on targets with a 
role in cancer epithelial to mesenchymal transition, migration and angiogenesis, processes in which 
both factors are known to be involved. In particular, CCNE2, which has been connected to migratory 
ability of tumoral cells (Caldon and Musgrove, 2010), has been proved to be under the transcriptional 
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control of HMGA1, thus promoting the migratory and invasive abilities of breast cancer cells 
(Pegoraro et al., 2015). Furthermore, HMGA1 has been also found to regulate the EMT, a process 
necessary to cell migration, by impacting on the WNT-beta catenin pathway, known to contribute to 
metastatization (DiMeo et al., 2009); indeed, HMGA1 regulates LEF1, one of the actor of this 
pathway (Pegoraro et al., 2013). Moreover, a few evidences highlighted a connection between 
HMGA1 and VEGFA, one of the main inducer of angiogenesis (Carmeliet and Jain, 2011) found to 
be under the transcriptional control of HMGA1, thus suggesting an involvement of HMGA1 in the 
angiogenic process, pivotal for tumor growth and dissemination. Taken into account these data, we 
validated the expression level of CCNE2, LEF1, SNAI2-another important factor involved in EMT- 
and VEGFA upon HMGA1 and FOXM1 silencing in triple negative breast cancer cell lines models. 
We were then able to validate the expression changes predicted by the bioinformatic analysis, 
confirming the involvement of HMGA1 and FOXM1 in the same gene network. Furthermore, by co-
silencing HMGA1 and FOXM1 in our model of TNBC, we observed a stronger reduction of the 
above-mentioned targets, suggesting that HMGA1 cooperates with its molecular partner FOXM1 in 
regulating these factors. A considerable amount of data sustains the involvement of FOXM1 in 
several features of breast cancer progression, such as the EMT, the migration and invasion abilities 
of tumour cells and tumoral angiogenesis, in which FOXM1 controls the transcription of several 
metalloproteinases, the EMT inducer SNAI2 and the angiogenic factor VEGFA (Saba et al., 2016). 
Taken into account these evidences and considering that the co-depletion of HMGA1 and FOXM1 in 
our TNBC model has an additive effect on the expression level of CCNE2, LEF1, SNAI2 and VEGFA 
with respect to the single silencing conditions, we inferred a common mechanism of action of 
HMGA1 and FOXM1 in important malignant hallmarks of TNBC, such as EMT, migration and 
angiogenic process, highlighting a dependence of breast tumor cells on HMGA1 and FOXM1 
synergic action. The cooperative action of HMGA1 and FOXM1 on breast cancer features is also 
confirmed by the in vivo injection of TNBC cells co-silenced for HMGA1 and FOXM1 in a model of 
Zebrafish. Indeed, it has been brought to light that the proliferation rate of breast cancer cells 
diminishes upon HMGA1 and FOXM1 co-depletion, proving the role of these factors in promoting 
in concert aggressive traits of triple negative breast cancer. Previously, a potentiating action of 
HMGA proteins on transcriptional activity of other transcription factors, such as NF-KB has been 
extensively studied (Cleynen et al., 2007; Yie et al., 1999b). Subsequently, considering the 
cooperative action of HMGA1 and FOXM1 on different biological aspects, we evaluated whether 
HMGA1 has a general impact on FOXM1 transcriptional activity. Indeed, we observed a potentiating 
action of HMGA1 on FOXM1 in regulating a synthetic promoter with its own binding sites, 
confirming the tight dependence of FOXM1 on HMGA1. Several studies support the idea that, in 
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order to exert its function of transcription factor, FOXM1 cellular localization has to be finely 
regulated and that it occurs mainly at a post-translational level (Jaiswal et al., 2014); moreover, 
considering that HMGA1 regulates FOXM1 transcriptional activity, we explored the possible ways 
of FOXM1 regulation by HMGA1. Upon HMGA1 action, we demonstrated that the endogenous and 
exogenous FOXM1 protein level and nuclear localization are affected by HMGA1. Thus, we 
speculated a new molecular mechanism of regulation of FOXM1, in which HMGA1 enhances 
FOXM1 transcriptional activity at a post-transcriptional level, by influencing the stability and thus 
the nuclear presence of FOXM1 on its targets. A profound molecular relation between HMGA1 and 
FOXM1 has been further highlighted by TCGA analysis on breast cancer patients, which confirmed 
a strong enrichment of FOXM1 presence in HMGA1 over-expressing patients, in particular in ER- 
cases, breast cancer subtype in which HMGA1 is highly expressed. All these results clearly confirm 
a fine dependence of FOXM1 on HMGA1, both for its cellular localization and subsequently for its 
transcriptional activity on pathways pivotal for breast cancer aggressive traits. Therefore, we 
considered that, among the hallmarks in which HMGA1 has a profound impact, the angiogenesis is 
the one in which HMGA1 role has been poorly explored. As one of the main inducer of angiogenesis, 
VEGFA is regulated by a plethora of factors; indeed, VEGFA promoter contains binding sites for 
several factors, such as Sp1/Sp3, AP-2, Egr-1, STAT3 and HIF1, which finely control VEGFA 
transcription depending on the patho-physiological situation, thus confirming VEGFA crucial impact 
on the angiogenic process (Pagès and Pouysségur, 2005). In particular, Sp1 is a potent inducer of 
VEGFA transcription and its down-regulation brings to a reduced tumor vascularization (Wei et al., 
2004). Literature data also highlight that HMGA1 and FOXM1 regulates VEGFA transcription 
(Messineo et al., 2016; Zhang et al., 2008) and our results confirmed the regulation of VEGFA by 
these two factors both independently but above all in a synergistical manner. In fact, we further 
deepened the action of HMGA1 and FOXM1 on VEGFA promoter by several reporter assays and we 
demonstrated for the first time that HMGA1 acts through two independent pathways in regulating 
VEGFA transcription: on one side, HMGA1 action depends on FOXM1, confirming once again the 
action of this factor on VEGFA transcription and a cooperation with HMGA1 in its transcriptional 
activity; on the other, HMGA1 regulates VEGFA through Sp1 in a different promoter region. The 
fact that HMGA1 could work with Sp1 in regulating gene transcription is also reported in the control 
of insulin receptor (IR) gene transcription, in which HMGA1 interacting with Sp1 and C/EBP beta 
facilitates the binding of both factors to the IR promoter and synergistically activates IR transcription 
(Foti et al., 2003). These evidences suggest a similar mechanism of action on VEGFA promoter via 
Sp1 and FOXM1. These results highlight that HMGA1 control VEGFA with different molecular 
partners and suggest a possible context-dependent VEGFA activation by HMGA1. Given the action 
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of HMGA1 and FOXM1 on VEGFA transcription, we wondered whether they influence the 
angiogenic process in general by evaluating the presence of other factors involved in angiogenesis or 
related processes. By crossing the DEG list upon HMGA1 silencing and FOXM1 IPA network, we 
found several factors connected to angiogenesis and related processes like vasculogenesis. Very 
interestingly, among these DEG, LEF1 and CCNE2 were already been validated as transcriptional 
targets of HMGA1 and FOXM1, not only independently but, more importantly, in a cooperative way. 
A lot of studies proved the causal role of HMGA1 at multiple stages of breast cancer progression, 
acting on proliferation of tumoral cells, thus on tumor growth (Shah et al., 2013), but also on 
migration and invasion abilities of cells, leading to metastatic dissemination (Pegoraro et al., 2013). 
An event which represents a fundamental step in cancer growth and metastatic spread is the formation 
of blood vessels by tumoral angiogenesis, which sustains the tumor mass with nutrients and oxygen 
and promotes the cancer cells to reach distal organs (Folkman, 2002). Among the multitude of factors 
inducing tumoral angiogenesis, HMGA1 and FOXM1 have been found to play an important part, 
considering not only the literature evidences, but also the results obtained in this work, strongly 
relating their transcriptional action on VEGFA and other angiogenic factors. We thus evaluated 
whether HMGA1 and FOXM1 can lead the TNBC cells to influence the surrounding tumoral 
environment and promote angiogenic events carried out by endothelial cells. In accordance to this, 
we previously demonstrated that HMGA1 has a profound impact in breast cancer cell secretome, 
inducing the release of a pool of pro-migratory proteins that act on breast cancer cells itself (Resmini 
et al., 2017). We then performed several in vitro experiments on endothelial cells induced by TNBC 
supernatants depleted for HMGA1 and FOXM1 and we proved the leading role of these factors in 
guiding breast cancer cells to secrete angiogenic factors, promoting the proliferation and the 
migration of endothelial cells and their ability to organize in vessel-like structures. We confirmed the 
angiogenic potential of HMGA1 and FOXM1 in breast cancer cells by injecting HMGA1 and 
FOXM1 depleted-TNBC cells in Zebrafish embryos, which are highly suitable animal models for the 
evaluation of the blood vessels formation (Tobia et al., 2011). We thus proved that the contemporary 
down-regulation of HMGA1 and FOXM1 severely impairs the in vivo angiogenic process of 
Zebrafish endothelial cells, confirming that HMGA1 and FOXM1 in concert profoundly impact on 
triple negative breast cancer cells in promoting the angiogenic process. HMGA1 is a highly plastic 
factor which, with its ability to bind non specific regions of the DNA and the possibility to interact 
with a high number of molecular partners, regulates several cellular processes, hallmarks of cancer, 
in a way dependent on the molecular context. In our study, we discovered a new partner of HMGA1, 
the transcription factor FOXM1: the cooperation with these factors has been proved to severely 
influence the angiogenic induction by breast cancer cells on surrounding endothelial cells, bringing 
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the idea of a higher impact of HMGA1 and FOXM1 on this hallmark with respect to others. In the 
last years, giving the importance of FOXM1 in cancer context, the perspective of targeting FOXM1 
has grown. Indeed, several anti-FOXM1 drugs have been tested, such as proteasome inhibitors like 
Thiostrepton and Syomicin A and the new small molecule FDI-6, which more specifically binds to 
FOXM1 protein and interferes with FOXM1 binding to DNA (Kalinichenko and Kalin, 2015). 
Considering that HMGA1 control several cellular pathways, which are intersected by FOXM1, and 
together they regulate common features of breast cancer aggressiveness, as we demonstrated in this 
work in the case of the angiogenesis process, deepening the molecular relationship occurring between 
HMGA1 and FOXM1 could be extremely useful to better target TNBC patients and to contribute to 
breast cancer defeat.       
 
In conclusion, with this study we demonstrated several major findings: 
 
1. HMGA1 and FOXM1 regulate a transcriptional network which control cancer hallmarks such as 
epithelial to mesenchymal transition, migration, invasion and angiogenesis, pivotal for triple 
negative breast cancer progression. 
 
2. HMGA1 regulates the VEGFA, one of the main inducer of angiogenesis and thus tumour growth 
and metastatic spread, through two mechanisms, an Sp1-dependent and a FOXM1-dependent 
ways. 
 
3. HMGA1 and FOXM1 control a common network of angiogenic factors secreted by TNBC cells 
which in turn modulate several angiogenic processes of endothelial cells. 
 
4. HMGA1 and FOXM1 synergistically induce the in vivo tumoral angiogenic process, a cancer 
hallmark fundamental for the acquisition of aggressive traits of breast cancer 
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Hypothetical model proposed: HMGA1 and FOXM1 synergistically influence the production 
of angiogenic factors, such as VEGFA, by the TNBC cells, which in turn modulate the 
angiogenesis carried out by endothelial cells 
 
 
 
 
 
 
84 
 
 
 
 
 
References 
 
 
 
 
 
85 
 
Ahn, H., Sim, J., Abdul, R., Chung, M.S., Paik, S.S., Oh, Y.-H., Park, C.K., and Jang, K. (2015). Increased 
expression of forkhead box M1 is associated with aggressive phenotype and poor prognosis in estrogen 
receptor-positive breast cancer. J. Korean Med. Sci. 30, 390–397. 
Auer, G.U., Caspersson, T.O., and Wallgren, A.S. (1980). DNA content and survival in mammary carcinoma. 
Anal. Quant. Cytol. 2, 161–165. 
Auer, G.U., Fallenius, A.G., Erhardt, K.Y., and Sundelin, B.S. (1984). Progression of mammary 
adenocarcinomas as reflected by nuclear DNA content. Cytometry 5, 420–425. 
Baldassarre, G., Belletti, B., Battista, S., Nicoloso, M.S., Pentimalli, F., Fedele, M., Croce, C.M., and Fusco, A. 
(2005). HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene 24, 6809–6819. 
Bektas, N., Haaf, A. ten, Veeck, J., Wild, P.J., Lüscher-Firzlaff, J., Hartmann, A., Knüchel, R., and Dahl, E. 
(2008). Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in 
human breast cancer. BMC Cancer 8, 42. 
Bowman, T., Garcia, R., Turkson, J., and Jove, R. (2000). STATs in oncogenesis. Oncogene 19, 2474–2488. 
Brennan, R.G. (1993). The winged-helix DNA-binding motif: another helix-turn-helix takeoff. Cell 74, 773–
776. 
Bruce, J., Carter, D.C., and Fraser, J. (1970). Patterns of recurrent disease in breast cancer. Lancet Lond. 
Engl. 1, 433–435. 
Caldon, C.E., and Musgrove, E.A. (2010). Distinct and redundant functions of cyclin E1 and cyclin E2 in 
development and cancer. Cell Div. 5, 2. 
Camós, S., Gubern, C., Sobrado, M., Rodríguez, R., Romera, V.G., Moro, M.A., Lizasoain, I., Serena, J., 
Mallolas, J., and Castellanos, M. (2014). The high-mobility group I-Y transcription factor is involved in 
cerebral ischemia and modulates the expression of angiogenic proteins. Neuroscience 269, 112–130. 
Carmeliet, P., and Jain, R.K. (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 
473, 298–307. 
Carr, J.R., Park, H.J., Wang, Z., Kiefer, M.M., and Raychaudhuri, P. (2010). FoxM1 Mediates Resistance to 
Herceptin and Paclitaxel. Cancer Res. 70, 5054–5063. 
Cavallaro, U., and Christofori, G. (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. 
Nat. Rev. Cancer 4, 118–132. 
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., 
Larsson, E., et al. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring 
Multidimensional Cancer Genomics Data. Cancer Discov. 2, 401–404. 
Chen, H., Zhu, G., Li, Y., Padia, R.N., Dong, Z., Pan, Z.K., Liu, K., and Huang, S. (2009). Extracellular signal-
regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. 
Cancer Res. 69, 9228–9235. 
Chiappetta, G., Avantaggiato, V., Visconti, R., Fedele, M., Battista, S., Trapasso, F., Merciai, B.M., Fidanza, V., 
Giancotti, V., Santoro, M., et al. (1996). High level expression of the HMGI (Y) gene during embryonic 
development. Oncogene 13, 2439–2446. 
86 
 
Chiappetta, G., Botti, G., Monaco, M., Pasquinelli, R., Pentimalli, F., Di Bonito, M., D’Aiuto, G., Fedele, M., 
Iuliano, R., Palmieri, E.A., et al. (2004). HMGA1 protein overexpression in human breast carcinomas: 
correlation with ErbB2 expression. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 10, 7637–7644. 
Chin, K., DeVries, S., Fridlyand, J., Spellman, P.T., Roydasgupta, R., Kuo, W.-L., Lapuk, A., Neve, R.M., Qian, 
Z., Ryder, T., et al. (2006). Genomic and transcriptional aberrations linked to breast cancer 
pathophysiologies. Cancer Cell 10, 529–541. 
Chin, M.T., Pellacani, A., Wang, H., Lin, S.S., Jain, M.K., Perrella, M.A., and Lee, M.E. (1998). Enhancement of 
serum-response factor-dependent transcription and DNA binding by the architectural transcription factor 
HMG-I(Y). J. Biol. Chem. 273, 9755–9760. 
Chung, A.S., Lee, J., and Ferrara, N. (2010). Targeting the tumour vasculature: insights from physiological 
angiogenesis. Nat. Rev. Cancer 10, 505–514. 
Cleynen, I., and Van de Ven, W.J.M. (2008). The HMGA proteins: a myriad of functions (Review). Int. J. 
Oncol. 32, 289–305. 
Cleynen, I., Brants, J.R., Peeters, K., Deckers, R., Debiec-Rychter, M., Sciot, R., Van de Ven, W.J.M., and Petit, 
M.M.R. (2007). HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in 
cooperation with nuclear factor-kappaB. Mol. Cancer Res. MCR 5, 363–372. 
Consoli, F., Grisanti, S., Amoroso, V., Almici, C., Verardi, R., Marini, M., and Simoncini, E. (2011). Circulating 
tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial. 
Tumori 97, 737–742. 
Currie, R.A. (1997). Functional interaction between the DNA binding subunit trimerization domain of NF-Y 
and the high mobility group protein HMG-I(Y). J. Biol. Chem. 272, 30880–30888. 
Dean, C.B., and Nielsen, J.D. (2007). Generalized linear mixed models: a review and some extensions. 
Lifetime Data Anal. 13, 497–512. 
Delov, V., Muth-Köhne, E., Schäfers, C., and Fenske, M. (2014). Transgenic fluorescent zebrafish 
Tg(fli1:EGFP)y1 for the identification of vasotoxicity within the zFET. Aquat. Toxicol. Amst. Neth. 150, 189–
200. 
DiMeo, T.A., Anderson, K., Phadke, P., Fan, C., Feng, C., Perou, C.M., Naber, S., and Kuperwasser, C. (2009). 
A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-
mesenchymal transition in basal-like breast cancer. Cancer Res. 69, 5364–5373. 
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, 
T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinforma. Oxf. Engl. 29, 15–21. 
Dvorak, H.F., Brown, L.F., Detmar, M., and Dvorak, A.M. (1995). Vascular permeability factor/vascular 
endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029–
1039. 
Fedele, M., and Fusco, A. (2010). HMGA and cancer. Biochim. Biophys. Acta 1799, 48–54. 
Fedele, M., Visone, R., De Martino, I., Troncone, G., Palmieri, D., Battista, S., Ciarmiello, A., Pallante, P., 
Arra, C., Melillo, R.M., et al. (2006a). HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. 
Cancer Cell 9, 459–471. 
87 
 
Fedele, M., Fidanza, V., Battista, S., Pentimalli, F., Klein-Szanto, A.J.P., Visone, R., De Martino, I., Curcio, A., 
Morisco, C., Del Vecchio, L., et al. (2006b). Haploinsufficiency of the Hmga1 gene causes cardiac 
hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res. 66, 2536–2543. 
Federico, A., Forzati, F., Esposito, F., Arra, C., Palma, G., Barbieri, A., Palmieri, D., Fedele, M., Pierantoni, 
G.M., De Martino, I., et al. (2014). Hmga1/Hmga2 double knock-out mice display a “superpygmy” 
phenotype. Biol. Open 3, 372–378. 
Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186. 
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15–18. 
Folkman, J., and Hanahan, D. (1991). Switch to the angiogenic phenotype during tumorigenesis. Princess 
Takamatsu Symp. 22, 339–347. 
Foti, D., Iuliano, R., Chiefari, E., and Brunetti, A. (2003). A nucleoprotein complex containing Sp1, C/EBP 
beta, and HMGI-Y controls human insulin receptor gene transcription. Mol. Cell. Biol. 23, 2720–2732. 
Foulkes, W.D., Grainge, M.J., Rakha, E.A., Green, A.R., and Ellis, I.O. (2009). Tumor size is an unreliable 
predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. 
Breast Cancer Res. Treat. 117, 199–204. 
Foulkes, W.D., Smith, I.E., and Reis-Filho, J.S. (2010). Triple-negative breast cancer. N. Engl. J. Med. 363, 
1938–1948. 
Fusco, A., and Fedele, M. (2007). Roles of HMGA proteins in cancer. Nat. Rev. Cancer 7, 899–910. 
Gannon, L.M., Cotter, M.B., and Quinn, C.M. (2013). The classification of invasive carcinoma of the breast. 
Expert Rev. Anticancer Ther. 13, 941–954. 
Gebeshuber, C.A., Sladecek, S., and Grunert, S. (2007). Beta-catenin/LEF-1 signalling in breast cancer--
central players activated by a plethora of inputs. Cells Tissues Organs 185, 51–60. 
Giacca, M., and Zacchigna, S. (2012). VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. 
Gene Ther. 19, 622–629. 
Giancotti, V., Pani, B., D’Andrea, P., Berlingieri, M.T., Di Fiore, P.P., Fusco, A., Vecchio, G., Crane-Robinson, 
C., and Goodwin, G.H. (1987). Histone and nonhistone proteins from normal and virus-transformed rat 
thyroid epithelial cells. Basic Appl. Histochem. 31, 229–238. 
Goi, M., and Childs, S.J. (2016). Patterning mechanisms of the sub-intestinal venous plexus in zebrafish. 
Dev. Biol. 409, 114–128. 
Goodman, O.B., Fink, L.M., Symanowski, J.T., Wong, B., Grobaski, B., Pomerantz, D., Ma, Y., Ward, D.C., and 
Vogelzang, N.J. (2009). Circulating tumor cells in patients with castration-resistant prostate cancer baseline 
values and correlation with prognostic factors. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer 
Res. Cosponsored Am. Soc. Prev. Oncol. 18, 1904–1913. 
Gould Rothberg, B.E., and Bracken, M.B. (2006). E-cadherin immunohistochemical expression as a 
prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. 
Breast Cancer Res. Treat. 100, 139–148. 
Greenberg, S., and Rugo, H.S. (2010). Triple-negative breast cancer: role of antiangiogenic agents. Cancer J. 
Sudbury Mass 16, 33–38. 
88 
 
Gu, G., Dustin, D., and Fuqua, S.A. (2016). Targeted therapy for breast cancer and molecular mechanisms of 
resistance to treatment. Curr. Opin. Pharmacol. 31, 97–103. 
Ha, T.-K., Her, N.-G., Lee, M.-G., Ryu, B.-K., Lee, J.-H., Han, J., Jeong, S.-I., Kang, M.-J., Kim, N.-H., Kim, H.-J., 
et al. (2012). Caveolin-1 increases aerobic glycolysis in colorectal cancers by stimulating HMGA1-mediated 
GLUT3 transcription. Cancer Res. 72, 4097–4109. 
Halasi, M., and Gartel, A.L. (2009). A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell 
Cycle Georget. Tex 8, 1966–1967. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57–70. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674. 
Harbeck, N., Kates, R.E., Schmitt, M., Gauger, K., Kiechle, M., Janicke, F., Thomassen, C., Look, M.P., and 
Foekens, J.A. (2004). Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome 
and therapy response in primary breast cancer. Clin. Breast Cancer 5, 348–352. 
Heitz, F., Harter, P., Lueck, H.-J., Fissler-Eckhoff, A., Lorenz-Salehi, F., Scheil-Bertram, S., Traut, A., and du 
Bois, A. (2009). Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an 
earlier occurrence of cerebral metastases. Eur. J. Cancer Oxf. Engl. 1990 45, 2792–2798. 
Herbert, S.P., and Stainier, D.Y.R. (2011). Molecular control of endothelial cell behaviour during blood 
vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551–564. 
Hicklin, D.J., and Ellis, L.M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth 
and angiogenesis. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 23, 1011–1027. 
Hillion, J., Dhara, S., Sumter, T.F., Mukherjee, M., Di Cello, F., Belton, A., Turkson, J., Jaganathan, S., Cheng, 
L., Ye, Z., et al. (2008). The high-mobility group A1a/signal transducer and activator of transcription-3 axis: 
an achilles heel for hematopoietic malignancies? Cancer Res. 68, 10121–10127. 
Hu, Z., Fan, C., Livasy, C., He, X., Oh, D.S., Ewend, M.G., Carey, L.A., Subramanian, S., West, R., Ikpatt, F., et 
al. (2009). A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 7, 
9. 
Ivaska, J., Pallari, H.-M., Nevo, J., and Eriksson, J.E. (2007). Novel functions of vimentin in cell adhesion, 
migration, and signaling. Exp. Cell Res. 313, 2050–2062. 
Jain, R.K. (1990). Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer 
Metastasis Rev. 9, 253–266. 
Jaiswal, N., Chakraborty, S., and Nag, A. (2014). BIOLOGY OF FOXM1 AND ITS EMERGING ROLE IN CANCER 
THERAPY. J. Proteins Proteomics 5. 
Jung, D.-W., Oh, E.-S., Park, S.-H., Chang, Y.-T., Kim, C.-H., Choi, S.-Y., and Williams, D.R. (2012). A novel 
zebrafish human tumor xenograft model validated for anti-cancer drug screening. Mol. Biosyst. 8, 1930–
1939. 
Kalin, T.V., Wang, I.-C., Ackerson, T.J., Major, M.L., Detrisac, C.J., Kalinichenko, V.V., Lyubimov, A., and 
Costa, R.H. (2006). Increased levels of the FoxM1 transcription factor accelerate development and 
progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66, 1712–1720. 
89 
 
Kalinichenko, V.V., and Kalin, T.V. (2015). Is there potential to target FOXM1 for “undruggable” lung 
cancers? Expert Opin. Ther. Targets 19, 865–867. 
Karadedou, C.T., Gomes, A.R., Chen, J., Petkovic, M., Ho, K.-K., Zwolinska, A.K., Feltes, A., Wong, S.Y., Chan, 
K.Y.K., Cheung, Y.-N., et al. (2012). FOXO3a represses VEGF expression through FOXM1-dependent and -
independent mechanisms in breast cancer. Oncogene 31, 1845–1858. 
Kelleher, F.C., and O’Sullivan, H. (2016). FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem 
cell pathways. Oncotarget 7, 42792–42804. 
Kelly, T., Yan, Y., Osborne, R.L., Athota, A.B., Rozypal, T.L., Colclasure, J.C., and Chu, W.S. (1998). Proteolysis 
of extracellular matrix by invadopodia facilitates human breast cancer cell invasion and is mediated by 
matrix metalloproteinases. Clin. Exp. Metastasis 16, 501–512. 
Kerbel, R.S. (2008). Tumor angiogenesis. N. Engl. J. Med. 358, 2039–2049. 
Kim, I.-M., Ramakrishna, S., Gusarova, G.A., Yoder, H.M., Costa, R.H., and Kalinichenko, V.V. (2005). The 
forkhead box m1 transcription factor is essential for embryonic development of pulmonary vasculature. J. 
Biol. Chem. 280, 22278–22286. 
Kocdor, M.A., Kocdor, H., Pereira, J.S., Vanegas, J.E., Russo, I.H., and Russo, J. (2013). Progressive increase 
of glucose transporter-3 (GLUT-3) expression in estrogen-induced breast carcinogenesis. Clin. Transl. Oncol. 
Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex. 15, 55–64. 
Koo, C.-Y., Muir, K.W., and Lam, E.W.-F. (2012). FOXM1: From cancer initiation to progression and 
treatment. Biochim. Biophys. Acta 1819, 28–37. 
Korver, W., Roose, J., and Clevers, H. (1997). The winged-helix transcription factor Trident is expressed in 
cycling cells. Nucleic Acids Res. 25, 1715–1719. 
Korver, W., Schilham, M.W., Moerer, P., van den Hoff, M.J., Dam, K., Lamers, W.H., Medema, R.H., and 
Clevers, H. (1998). Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the 
winged-helix transcription factor Trident. Curr. Biol. CB 8, 1327–1330. 
Kronenwett, U., Huwendiek, S., Ostring, C., Portwood, N., Roblick, U.J., Pawitan, Y., Alaiya, A., Sennerstam, 
R., Zetterberg, A., and Auer, G. (2004). Improved grading of breast adenocarcinomas based on genomic 
instability. Cancer Res. 64, 904–909. 
Kronenwett, U., Ploner, A., Zetterberg, A., Bergh, J., Hall, P., Auer, G., and Pawitan, Y. (2006). Genomic 
instability and prognosis in breast carcinomas. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer 
Res. Cosponsored Am. Soc. Prev. Oncol. 15, 1630–1635. 
Kwok, J.M.-M., Peck, B., Monteiro, L.J., Schwenen, H.D.C., Millour, J., Coombes, R.C., Myatt, S.S., and Lam, 
E.W.-F. (2010). FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. MCR 8, 
24–34. 
Lam, E.W.-F., Brosens, J.J., Gomes, A.R., and Koo, C.-Y. (2013). Forkhead box proteins: tuning forks for 
transcriptional harmony. Nat. Rev. Cancer 13, 482–495. 
Laoukili, J., Kooistra, M.R.H., Brás, A., Kauw, J., Kerkhoven, R.M., Morrison, A., Clevers, H., and Medema, 
R.H. (2005). FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat. Cell 
Biol. 7, 126–136. 
90 
 
Laoukili, J., Stahl, M., and Medema, R.H. (2007). FoxM1: at the crossroads of ageing and cancer. Biochim. 
Biophys. Acta 1775, 92–102. 
Lehtinen, L., Ketola, K., Mäkelä, R., Mpindi, J.-P., Viitala, M., Kallioniemi, O., and Iljin, K. (2013). High-
throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator 
of breast cancer cell migration and invasion. Oncotarget 4, 48–63. 
Lim, E., Vaillant, F., Wu, D., Forrest, N.C., Pal, B., Hart, A.H., Asselin-Labat, M.-L., Gyorki, D.E., Ward, T., 
Partanen, A., et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor 
development in BRCA1 mutation carriers. Nat. Med. 15, 907–913. 
Littler, D.R., Alvarez-Fernández, M., Stein, A., Hibbert, R.G., Heidebrecht, T., Aloy, P., Medema, R.H., and 
Perrakis, A. (2010). Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence. 
Nucleic Acids Res. 38, 4527–4538. 
Loges, S., Mazzone, M., Hohensinner, P., and Carmeliet, P. (2009). Silencing or fueling metastasis with VEGF 
inhibitors: antiangiogenesis revisited. Cancer Cell 15, 167–170. 
Lund, T., Holtlund, J., Fredriksen, M., and Laland, S.G. (1983). On the presence of two new high mobility 
group-like proteins in HeLa S3 cells. FEBS Lett. 152, 163–167. 
Ma, R.Y.M., Tong, T.H.K., Cheung, A.M.S., Tsang, A.C.C., Leung, W.Y., and Yao, K.-M. (2005). Raf/MEK/MAPK 
signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J. Cell Sci. 118, 795–
806. 
Macias, H., and Hinck, L. (2012). Mammary gland development. Wiley Interdiscip. Rev. Dev. Biol. 1, 533–
557. 
Madureira, P.A., Varshochi, R., Constantinidou, D., Francis, R.E., Coombes, R.C., Yao, K.-M., and Lam, E.W.-F. 
(2006). The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast 
cancer cells. J. Biol. Chem. 281, 25167–25176. 
Malhotra, G.K., Zhao, X., Band, H., and Band, V. (2010). Histological, molecular and functional subtypes of 
breast cancers. Cancer Biol. Ther. 10, 955–960. 
Manders, P., Beex, L.V. a. M., Tjan-Heijnen, V.C.G., Geurts-Moespot, J., Van Tienoven, T.H., Foekens, J.A., 
and Sweep, C.G.J. (2002). The prognostic value of vascular endothelial growth factor in 574 node-negative 
breast cancer patients who did not receive adjuvant systemic therapy. Br. J. Cancer 87, 772–778. 
Messineo, S., Laria, A.E., Arcidiacono, B., Chiefari, E., Luque Huertas, R.M., Foti, D.P., and Brunetti, A. 
(2016). Cooperation between HMGA1 and HIF-1 Contributes to Hypoxia-Induced VEGF and Visfatin Gene 
Expression in 3T3-L1 Adipocytes. Front. Endocrinol. 7, 73. 
Millour, J., de Olano, N., Horimoto, Y., Monteiro, L.J., Langer, J.K., Aligue, R., Hajji, N., and Lam, E.W.F. 
(2011). ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and 
resistance. Mol. Cancer Ther. 10, 1046–1058. 
Minn, A.J., Kang, Y., Serganova, I., Gupta, G.P., Giri, D.D., Doubrovin, M., Ponomarev, V., Gerald, W.L., 
Blasberg, R., and Massagué, J. (2005). Distinct organ-specific metastatic potential of individual breast 
cancer cells and primary tumors. J. Clin. Invest. 115, 44–55. 
Moran, M.S. (2015). Radiation therapy in the locoregional treatment of triple-negative breast cancer. 
Lancet Oncol. 16, e113-122. 
91 
 
Myatt, S.S., Kongsema, M., Man, C.W.-Y., Kelly, D.J., Gomes, A.R., Khongkow, P., Karunarathna, U., Zona, S., 
Langer, J.K., Dunsby, C.W., et al. (2014). SUMOylation inhibits FOXM1 activity and delays mitotic transition. 
Oncogene 33, 4316–4329. 
Nestal de Moraes, G., Delbue, D., Silva, K.L., Robaina, M.C., Khongkow, P., Gomes, A.R., Zona, S., Crocamo, 
S., Mencalha, A.L., Magalhães, L.M., et al. (2015). FOXM1 targets XIAP and Survivin to modulate breast 
cancer survival and chemoresistance. Cell. Signal. 27, 2496–2505. 
Nicholson, R.I., McClelland, R.A., Robertson, J.F., and Gee, J.M. (1999). Involvement of steroid hormone and 
growth factor cross-talk in endocrine response in breast cancer. Endocr. Relat. Cancer 6, 373–387. 
Oakes, S.R., Gallego-Ortega, D., and Ormandy, C.J. (2014). The mammary cellular hierarchy and breast 
cancer. Cell. Mol. Life Sci. CMLS 71, 4301–4324. 
Pagès, G., and Pouysségur, J. (2005). Transcriptional regulation of the Vascular Endothelial Growth Factor 
gene--a concert of activating factors. Cardiovasc. Res. 65, 564–573. 
Pang, B., Fan, H., Zhang, I.Y., Liu, B., Feng, B., Meng, L., Zhang, R., Sadeghi, S., Guo, H., and Pang, Q. (2012). 
HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and 
angiogenesis. J. Neurooncol. 106, 543–549. 
Paonessa, F., Foti, D., Costa, V., Chiefari, E., Brunetti, G., Leone, F., Luciano, F., Wu, F., Lee, A.S., Gulletta, E., 
et al. (2006). Activator protein-2 overexpression accounts for increased insulin receptor expression in 
human breast cancer. Cancer Res. 66, 5085–5093. 
Park, H.J., Costa, R.H., Lau, L.F., Tyner, A.L., and Raychaudhuri, P. (2008). Anaphase-promoting 
complex/cyclosome-CDH1-mediated proteolysis of the forkhead box M1 transcription factor is critical for 
regulated entry into S phase. Mol. Cell. Biol. 28, 5162–5171. 
Park, H.J., Gusarova, G., Wang, Z., Carr, J.R., Li, J., Kim, K.-H., Qiu, J., Park, Y.-D., Williamson, P.R., Hay, N., et 
al. (2011). Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol. Med. 3, 21–34. 
Patel, N.A., Patel, P.S., and Vora, H.H. (2015). Role of PRL-3, Snail, Cytokeratin and Vimentin expression in 
epithelial mesenchymal transition in breast carcinoma. Breast Dis. 35, 113–127. 
Pegoraro, S., Ros, G., Piazza, S., Sommaggio, R., Ciani, Y., Rosato, A., Sgarra, R., Del Sal, G., and Manfioletti, 
G. (2013). HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. 
Oncotarget 4, 1293–1308. 
Pegoraro, S., Ros, G., Ciani, Y., Sgarra, R., Piazza, S., and Manfioletti, G. (2015). A novel HMGA1-CCNE2-YAP 
axis regulates breast cancer aggressiveness. Oncotarget 6, 19087–19101. 
Pierantoni, G.M., Agosti, V., Fedele, M., Bond, H., Caliendo, I., Chiappetta, G., Lo Coco, F., Pane, F., Turco, 
M.C., Morrone, G., et al. (2003). High-mobility group A1 proteins are overexpressed in human leukaemias. 
Biochem. J. 372, 145–150. 
Pilarsky, C., Wenzig, M., Specht, T., Saeger, H.D., and Grützmann, R. (2004). Identification and validation of 
commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia N. Y. N 6, 
744–750. 
Pore, N., Liu, S., Shu, H.-K., Li, B., Haas-Kogan, D., Stokoe, D., Milanini-Mongiat, J., Pages, G., O’Rourke, 
D.M., Bernhard, E., et al. (2004). Sp1 is involved in Akt-mediated induction of VEGF expression through an 
HIF-1-independent mechanism. Mol. Biol. Cell 15, 4841–4853. 
92 
 
Prat, A., and Perou, C.M. (2009). Mammary development meets cancer genomics. Nat. Med. 15, 842–844. 
Rafii, S., Lyden, D., Benezra, R., Hattori, K., and Heissig, B. (2002). Vascular and haematopoietic stem cells: 
novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826–835. 
Ram, T.G., Reeves, R., and Hosick, H.L. (1993). Elevated high mobility group-I(Y) gene expression is 
associated with progressive transformation of mouse mammary epithelial cells. Cancer Res. 53, 2655–2660. 
Reeves, R. (2001). Molecular biology of HMGA proteins: hubs of nuclear function. Gene 277, 63–81. 
Reeves, R., and Adair, J.E. (2005). Role of high mobility group (HMG) chromatin proteins in DNA repair. DNA 
Repair 4, 926–938. 
Reeves, R., and Wolffe, A.P. (1996). Substrate structure influences binding of the non-histone protein HMG-
I(Y) to free nucleosomal DNA. Biochemistry (Mosc.) 35, 5063–5074. 
Reeves, R., Leonard, W.J., and Nissen, M.S. (2000). Binding of HMG-I(Y) imparts architectural specificity to a 
positioned nucleosome on the promoter of the human interleukin-2 receptor alpha gene. Mol. Cell. Biol. 
20, 4666–4679. 
Resmini, G., Rizzo, S., Franchin, C., Zanin, R., Penzo, C., Pegoraro, S., Ciani, Y., Piazza, S., Arrigoni, G., Sgarra, 
R., et al. (2017). HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer 
cells. Sci. Rep. 7, 11768. 
Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinforma. Oxf. Engl. 26, 139–140. 
Rydén, L., Jirström, K., Haglund, M., Stål, O., and Fernö, M. (2010). Epidermal growth factor receptor and 
vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. 
Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res. Treat. 120, 491–
498. 
Saba, R., Alsayed, A., Zacny, J.P., and Dudek, A.Z. (2016). The Role of Forkhead Box Protein M1 in Breast 
Cancer Progression and Resistance to Therapy. Int. J. Breast Cancer 2016, 9768183. 
Scholzen, T., and Gerdes, J. (2000). The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 
182, 311–322. 
Scully, O.J., Bay, B.-H., Yip, G., and Yu, Y. (2012). Breast cancer metastasis. Cancer Genomics Proteomics 9, 
311–320. 
Sgarra, R., Rustighi, A., Tessari, M.A., Di Bernardo, J., Altamura, S., Fusco, A., Manfioletti, G., and Giancotti, 
V. (2004). Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. 
FEBS Lett. 574, 1–8. 
Sgarra, R., Zammitti, S., Lo Sardo, A., Maurizio, E., Arnoldo, L., Pegoraro, S., Giancotti, V., and Manfioletti, G. 
(2010). HMGA molecular network: From transcriptional regulation to chromatin remodeling. Biochim. 
Biophys. Acta 1799, 37–47. 
Shah, S.N., Cope, L., Poh, W., Belton, A., Roy, S., Talbot, C.C., Sukumar, S., Huso, D.L., and Resar, L.M.S. 
(2013). HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PloS One 8, 
e63419. 
93 
 
Skibinski, A., and Kuperwasser, C. (2015). The origin of breast tumor heterogeneity. Oncogene 34, 5309–
5316. 
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G., and Klagsbrun, M. (1998). Neuropilin-1 is expressed by 
endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 
735–745. 
Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., 
Jeffrey, S.S., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with 
clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98, 10869–10874. 
Sternlicht, M.D. (2006). Key stages in mammary gland development: the cues that regulate ductal 
branching morphogenesis. Breast Cancer Res. BCR 8, 201. 
Sumter, T.F., Xian, L., Huso, T., Koo, M., Chang, Y.-T., Almasri, T.N., Chia, L., Inglis, C., Reid, D., and Resar, 
L.M.S. (2016). The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development. Curr. Mol. 
Med. 16, 353–393. 
Tanaka, M., Watanabe, T., Tamaki, S., Ichihara, T., Yasushi, T., Abe, T., Masakazu, T., and Nakashima, N. 
(1993). Revascularization in fibromuscular dysplasia of the coronary arteries. Am. Heart J. 125, 1167–1170. 
Teh, M.-T., Wong, S.-T., Neill, G.W., Ghali, L.R., Philpott, M.P., and Quinn, A.G. (2002). FOXM1 is a 
downstream target of Gli1 in basal cell carcinomas. Cancer Res. 62, 4773–4780. 
Timms, J.F., White, S.L., O’Hare, M.J., and Waterfield, M.D. (2002). Effects of ErbB-2 overexpression on 
mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene 21, 6573–
6586. 
Tobia, C., De Sena, G., and Presta, M. (2011). Zebrafish embryo, a tool to study tumor angiogenesis. Int. J. 
Dev. Biol. 55, 505–509. 
Tong, R.T., Boucher, Y., Kozin, S.V., Winkler, F., Hicklin, D.J., and Jain, R.K. (2004). Vascular normalization by 
vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature 
and improves drug penetration in tumors. Cancer Res. 64, 3731–3736. 
Tonon, F., Zennaro, C., Dapas, B., Carraro, M., Mariotti, M., and Grassi, G. (2016). Rapid and cost-effective 
xenograft hepatocellular carcinoma model in Zebrafish for drug testing. Int. J. Pharm. 515, 583–591. 
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 
2012. CA. Cancer J. Clin. 65, 87–108. 
Ueda, Y., Watanabe, S., Tei, S., Saitoh, N., Kuratsu, J.-I., and Nakao, M. (2007). High mobility group protein 
HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest. Cancer Sci. 98, 1893–1901. 
Vargo-Gogola, T., and Rosen, J.M. (2007). Modelling breast cancer: one size does not fit all. Nat. Rev. 
Cancer 7, 659–672. 
van ’t Veer, L.J., Dai, H., van de Vijver, M.J., He, Y.D., Hart, A.A.M., Mao, M., Peterse, H.L., van der Kooy, K., 
Marton, M.J., Witteveen, A.T., et al. (2002). Gene expression profiling predicts clinical outcome of breast 
cancer. Nature 415, 530–536. 
Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M.L., Park, H.J., Tan, Y., Ackerson, T., and Costa, R.H. 
(2005a). Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression 
and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 25, 10875–10894. 
94 
 
Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M.L., Park, H.J., Tan, Y., Ackerson, T., and Costa, R.H. 
(2005b). Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression 
and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol. Cell. Biol. 25, 10875–10894. 
Wang, X., Quail, E., Hung, N.J., Tan, Y., Ye, H., and Costa, R.H. (2001). Increased levels of forkhead box M1B 
transcription factor in transgenic mouse hepatocytes prevent age-related proliferation defects in 
regenerating liver. Proc. Natl. Acad. Sci. U. S. A. 98, 11468–11473. 
Wang, X., Kiyokawa, H., Dennewitz, M.B., and Costa, R.H. (2002). The Forkhead Box m1b transcription 
factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc. Natl. 
Acad. Sci. U. S. A. 99, 16881–16886. 
Wang, Z., Banerjee, S., Kong, D., Li, Y., and Sarkar, F.H. (2007). Down-regulation of Forkhead Box M1 
transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer 
Res. 67, 8293–8300. 
Watanabe, M., Ni, S., Lindenberger, A.L., Cho, J., Tinch, S.L., and Kennedy, M.A. (2013). Characterization of 
the Stoichiometry of HMGA1/DNA Complexes. Open Biochem. J. 7, 73–81. 
Webber, C., Gospodarowicz, M., Sobin, L.H., Wittekind, C., Greene, F.L., Mason, M.D., Compton, C., Brierley, 
J., and Groome, P.A. (2014). Improving the TNM classification: findings from a 10-year continuous literature 
review. Int. J. Cancer 135, 371–378. 
Wei, D., Wang, L., He, Y., Xiong, H.Q., Abbruzzese, J.L., and Xie, K. (2004). Celecoxib inhibits vascular 
endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic 
cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64, 2030–2038. 
Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E.N., Moore, D.H., Meli, S., and Gasparini, G. 
(1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast 
carcinoma. J. Natl. Cancer Inst. 84, 1875–1887. 
Weigel, M.T., and Dowsett, M. (2010). Current and emerging biomarkers in breast cancer: prognosis and 
prediction. Endocr. Relat. Cancer 17, R245-262. 
Weigelt, B., Peterse, J.L., and van ’t Veer, L.J. (2005). Breast cancer metastasis: markers and models. Nat. 
Rev. Cancer 5, 591–602. 
Weigelt, B., Mackay, A., A’hern, R., Natrajan, R., Tan, D.S.P., Dowsett, M., Ashworth, A., and Reis-Filho, J.S. 
(2010). Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet 
Oncol. 11, 339–349. 
Weis, S.M., and Cheresh, D.A. (2011). Tumor angiogenesis: molecular pathways and therapeutic targets. 
Nat. Med. 17, 1359–1370. 
Wierstra, I., and Alves, J. (2007). FOXM1, a typical proliferation-associated transcription factor. Biol. Chem. 
388, 1257–1274. 
Wonsey, D.R., and Follettie, M.T. (2005). Loss of the forkhead transcription factor FoxM1 causes 
centrosome amplification and mitotic catastrophe. Cancer Res. 65, 5181–5189. 
Xue, J., Lin, X., Chiu, W.-T., Chen, Y.-H., Yu, G., Liu, M., Feng, X.-H., Sawaya, R., Medema, R.H., Hung, M.-C., 
et al. (2014). Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer 
metastasis. J. Clin. Invest. 124, 564–579. 
95 
 
Yang, C., Chen, H., Tan, G., Gao, W., Cheng, L., Jiang, X., Yu, L., and Tan, Y. (2013). FOXM1 promotes the 
epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. 
Cancer Lett. 340, 104–112. 
Yao, K.M., Sha, M., Lu, Z., and Wong, G.G. (1997). Molecular analysis of a novel winged helix protein, WIN. 
Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J. Biol. 
Chem. 272, 19827–19836. 
Ye, H., Kelly, T.F., Samadani, U., Lim, L., Rubio, S., Overdier, D.G., Roebuck, K.A., and Costa, R.H. (1997). 
Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal 
cells of embryonic and adult tissues. Mol. Cell. Biol. 17, 1626–1641. 
Yie, J., Merika, M., Munshi, N., Chen, G., and Thanos, D. (1999a). The role of HMG I(Y) in the assembly and 
function of the IFN-beta enhanceosome. EMBO J. 18, 3074–3089. 
Yie, J., Merika, M., Munshi, N., Chen, G., and Thanos, D. (1999b). The role of HMG I(Y) in the assembly and 
function of the IFN-beta enhanceosome. EMBO J. 18, 3074–3089. 
Zachary, I., and Gliki, G. (2001). Signaling transduction mechanisms mediating biological actions of the 
vascular endothelial growth factor family. Cardiovasc. Res. 49, 568–581. 
Zhang, Y., Zhang, N., Dai, B., Liu, M., Sawaya, R., Xie, K., and Huang, S. (2008). FoxM1B transcriptionally 
regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of 
glioma cells. Cancer Res. 68, 8733–8742. 
Zhao, Y., and Adjei, A.A. (2015). Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular 
Endothelial Growth Factor. The Oncologist 20, 660–673. 
Zhao, K., Käs, E., Gonzalez, E., and Laemmli, U.K. (1993). SAR-dependent mobilization of histone H1 by 
HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin. EMBO J. 12, 3237–3247. 
 
 
 
 
 
 
 
 
 
 
 
96 
 
 
 
 
 
 
 
 
 
 
 
 
Publications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
During my PhD, I contributed to the following work: 
 
“HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells” 
Giulia Resmini, Serena Rizzo, Cinzia Franchin, Rossella Zanin, Carlotta Penzo, Silvia Pegoraro, 
Yari Ciani, Silvano Piazza, Giorgio Arrigoni, Riccardo Sgarra and Guidalberto Manfioletti, 2017 
Scientific Reports   
 
Cancer cells secrete proteins that modify the extracellular environment acting as autocrine and 
paracrine stimulatory factors and have a relevant role in cancer progression. The HMGA1 oncofetal 
protein has a prominent role in controlling the expression of an articulated set of genes involved in 
various aspect of cancer cell transformation. However, little is known about its role in influencing the 
secretome of cancer cells. Performing an iTRAQ LC–MS/MS screening for the identification of 
secreted proteins, in an inducible model of HMGA1 silencing in breast cancer cells, we found that 
HMGA1 has a profound impact on cancer cell secretome. We demonstrated that the pool of HMGA1–
linked secreted proteins has pro–migratory and pro-invasive stimulatory roles. From an inspection of 
the HMGA1–dependent secreted factors it turned out that HMGA1 influences the presence in the 
extra cellular milieu of key components of the Plasminogen activation system (PLAU, SERPINE1, 
and PLAUR) that has a prominent role in promoting metastasis, and that HMGA1 has a direct role in 
regulating the transcription of two of them, i.e. PLAU and SERPINE1. The ability of HMGA1 to 
regulate the plasminogen activator system may constitute an important mechanism by which HMGA1 
promotes cancer progression. 
 
 
